

“EVALUATION OF SERUM MAGNESIUM LEVEL IN PRETERM LABOUR”

DISSERTATION SUBMITTED TO
SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH
KOLAR, KARNATAKA



IN PARTIAL FULFILLMENT OF THE REQUIREMENT FOR THE
DEGREE OF

M.S. IN OBSTETRICS AND GYNAECOLOGY

BY

DR. PHURAILATPAM. PRIYADARSHINI MBBS

UNDER THE GUIDANCE OF

DR.GOMATHY.E

&

Under the Co-Guidance of

Dr.Sumathi M.E

Associate Professor, Department of Biochemistry



**DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY
SRI DEVARAJ URS MEDICAL COLLEGE,
TAMAKA, KOLAR**

2017

**SRI DEVARAJ URS ACADEMY OF HIGHER
EDUCATION AND RESEARCH, KOLAR, KARNATAKA.**

DECLARATION BY THE CANDIDATE

I, **DR.PHURAILATPAM. PRIYADARSHINI**, hereby declare that this dissertation/thesis **entitled “EVALUATION OF SERUM MAGNESIUM LEVEL IN PRETERM LABOUR”** is a bonafide and genuine research work carried out by me under the guidance of **PROF. GOMATHY. E.**

Date: _____ **signature of the candidate**

Place: _____ **(DR. PHURAILATPAM PRIYADARSHINI, MBBS)**

CERTIFICATE BY THE GUIDE

This is to certify that the dissertation entitled “**EVALUATION OF SERUM MAGNISIUUM LEVEL IN PRETERM LABOUR**” is a bonafide research work done by **DR. PHURAILATPAM. PRIYADARSHINI**, in partial fulfilment of the requirement for the degree of **M.S, O.B.G.**

Date:

Place

Signature of the guide

DR. GOMATHY.E, MD

Professor, Dept. of Obstetrics and
Gynaecology

Sri Devaraj Urs Medical
College, Tamaka, Kolar

CERTIFICATE BY THE CO-GUIDE

This is to certify that the dissertation entitled “**EVALUATION OF SERUM MAGNESIUM LEVEL IN PRETERM LABOUR**” is a bonafide and genuine research work carried out by

DR. PHURAILATPAM.PRIYADARSHINI in partial fulfillment of the requirement for the degree of M.S. Obstetrics & Gynaecology.

DATE

Signature of the Co-guide

PLACE:

DR.SUMATHI. M.E

Associate professor, Department of
Biochemistry

Sri Devaraj Urs Medical College
Tamaka , Kolar.

ENDORSEMENT BY THE HOD, PRINCIPAL/HEAD OF THE INSTITUTION

This is to certify that the dissertation entitled “**EVALUATION OF SERUM MAGNESIUM LEVEL IN PRETERM LABOUR**” is a bonafide research work done by **HURAILATPAM. PRIYADARSHINI** under the guidance of **PROF. GOMATHY.E**

Seal & Signature of the HOD

(PROF. SHEELA. SR)

Seal & Signature of the Principal

(DR. HARENDRA KUMAR)

Date :

Place :

COPYRIGHT

DECLARATION BY THE CANDIDATE

I here by declare that the **SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH, DEEMED TO BE UNIVERSITY**, Karnataka shall have the right to preserve, use and disseminate this dissertation in print or electronic format for academic/ research purpose.

Date :

Signature of the candidate

Place:

DR. PHURAILATPAM. PRIYADARSHINI

**SRI DEVARAJ URS MEDICAL COLLEGE,
TAMAKA, KOLAR**

ETHICAL COMMITTEE CERTIFICATE

This is to certify, the ethical committee of Sri Devaraj Urs medical college, Tamaka, Kolar has unanimously approved **DR. PHURAILATPAM. PRIYADARSHINI** post graduate resident in the subject of obstetrics and gynaecology at Sri Devaraj Urs medical college, Tamaka, Kolar to take up the dissertation work titled **“EVALUATION OF SERUM MAGNESIUM LEVEL IN PRETERM LABOUR”** to be submitted to Sri Devaraj Urs Academy Of Higher education and Research, Kolar.

Signature of Member Secretary

ACKNOWLEDGEMENT

It is with deep sense of gratitude and respect, I take an opportunity to thank my teacher and guide **Dr.GOMATH.E** Professor, Department of obstetrics and Gynecology, Sri Devaraj Urs Medical College, Tamaka, Kolar, for his constant inspiration and valuable guidance at various stages of preparation of this dissertation.

I am also grateful to **DR.SUMATHI**, Associate professor Department of Biochemistry for consenting to be my Co-guide and giving valuable inputs during my study.

I am thankful to **Dr. SHEELA.SR.** Professors and HOD, as well as **DR. MUNIKRISHAN** and **DR. HEMALATHA.M**, Professors in department of Obstetrics & Gynaecology for their guidance during the course of my study.

I express my deepest gratitude to my post graduate colleagues **DR. LISTON, DR. SUNANDA, DR. SHILPA, DR.SHILPI, DR. PUJITHA** who lent me a helping hand in the completion of the dissertation and their valuable support and friendship during this study. I also like to convey my gratitude towards my juniors for all the help and

I would like to acknowledge the opportune help and permission rendered by the **Medical Director, Principle and Medical Superintendent**, Sri Devaraj Urs Medical College, RLJH, in conducting this study.

I express my deepest sense of gratitude to my father **DR. JILASANA SHARMA** and my mother **SMT. SATYABATI. DEVI** for their encouragement, unabated inspiration and moral support during my career as a postgraduate.

I also like to thank my sisters **DR. SUPRIYA** and **DR. AMRITA** and my brothers **DR. JAYADEVA** and **VASHISH** for their valuable support, love and encouragement

in every possible way.

Lastly I want to express my deep gratitude to my sister-in-law, **DR. MUKTA** and my brother-in-law **SAURAV SRIVASTHAVA** for their kindness and encouragement.

Thanking you all with all my Heart.

Date :

Signature of the candidate

Place:

(DR.PHURAILATPAM.PRIYADARSHINI)

ABBREVIATIONS

AFI	Amniotic Fluid Index
ART	Assisted Reproductive Technology
UTI	Urinary Tract Infection
BPP	Bio Physical profile
USG	Ultrasonography
TVU	Transvaginal ultrasonography
CTG	Cardio tocogram
CRH	Corticotrophin Releasing hormone
LDH	Lactate Dehydrogenase
HCG	Human chorionic Gonadotrophin
ICH	Intra Cranial Hemorrhage
PROM	Premature rupture of membranes
PPROM	Preterm premature rupture of membranes
PTB	Preterm birth
SMFM	Society for Maternal- Fetal Medicine
SGA	Small for gestational age
LGA	Large for gestational age
LLETZ	Large loop excision of transformation zone

TABLE OF CONTENTS

SL.No	CONTENTS	PAGE NO
1	INTRODUCTION	1
2	AIMS & OBJECTIVES	3
3	REVIEW OF LITERATURE	4
4	MATERIALS AND METHODS	58
5	OBSERVATION & ANALYSIS	63
6	DISCUSSION	78
7	CONCLUSION	83
8	SUMMARY	84
9	BIBLIOGRAPHY	85
10	ANNEXURES	102

LIST OF TABLES

1.	Frequency of death and major, intermediate and minor morbidity. Data are n (%)	15
2.	Survival and disability rates for 5736 live births born between 22 weeks and 26 weeks gestation at 20 medical centres in the United States during 2003 to 2007.	16
3.	Comparison of age in years in Study and Control group	64
4.	Distribution of parity in study and control group.	65
5.	The comparison of gestational age in study and control group	66
6.	The comparison of Socioeconomic status in study and control group.	67
7.	.Distribution of mode of delivery in study and control group:	68
8.	The comparison of sex of baby in study and control group:	69
9.	The comparison of birth weight of baby (Kg) in study and control group.	70
10.	The comparison of APGAR SCORE in study (N=50) and control (N=50) group	71
11.	Comparison of neonatal outcome in study (N=50) and control (N=50) group.	72

12.	Comparison of mean Serum Mg mEq/L across study groups (N=50) and control group (N=50).	73
13.	Distribution of mean magnesium (mEq/L) in different Socioeconomic status in study and control group.	75

LIST OF FIGURES

1.	Causes of neonatal death in india.	9
2.	Uterine myocyte relaxation and contraction	14
3.	Mechanism Of Infection Induced Preterm Labor	22
4.	Diagnosis of preterm labor	42
5.	Bar chart of Age distribution among study and control group.	64
6.	Bar chart of parity distribution in study population (N=50) and control population (N=50).	65
7.	Bar chart of Gestational age distribution in study population (N=50) and control population (N=50).	66
8.	Bar chart of Socioeconomic status distribution in study population (N=50) and control population (N=50).	67
9.	Bar chart of sex of baby in study population (N=50)	69
10.	Bar chart of weight of baby (Kg) in study population (N=50) and control population (N=50).	70
11.	Bar chart of AGPAR between study group (N=50) and control group (N=50).	71
12.	Bar chart of NEONATAL OUTCOME between study	72

	group (N=50) and control group (N=50).	
13.	Bar chart distribution of Serum Mg in study group (N=50) and control group.	73
14.	Box and whisker plot of distribution of Mg level in mEq/L in study group (N=50) and control group(N=50)	74
15.	Bar chart of Socioeconomic Status distribution in study and control group.	76
16.	Box and whisker plot of Serum Mg level (mEq/L) in different Socioeconomic Status between study and control group.	76
17.	Correlation between Gestational age at time of testing and serum Mg (mEq/L) in the study group (N=50) and control Group (N=50).	77

ABSTRACT

INTRODUCTION:

Preterm labour followed by preterm delivery is a major issue for perinatal morbidity and mortality¹. Preterm infants are at a greater risk of short term and long term complications including disabilities and impediments in growth and mental development. Incidence of preterm labour in India between 1980 -2000 is 5-10% leading to 70-80% of perinatal deaths¹. The aim of this study is to determine the relationship between serum magnesium level and preterm delivery, so that the high morbidity and mortality related to prematurity could be reduced by early diagnosis of this deficiency and its correction

STUDY DESIGN: Prospective case control study.

DURATION OF STUDY: October 2015 to October 2017.

PLACE OF STUDY: R.L.Jalappa Hospital and Research Centre Tamaka, Kolar.

METHODOLOGY: The study consisted of 50 pregnant women with preterm onset of labour (between 28 and 37 weeks of gestation) and 50 pregnant women with comparable gestational age (28 -37 weeks) attending the OPD for routine ANC and they are followed up till delivery. Venous blood sample of 2 ml is collected and the serum magnesium is estimated by Fusion 5.1 FS magnesium Micro slide method.

RESULTS: The mean age of the patients in the study group was 22.4 ± 3.084 while that in the control group was 22.4 ± 3.064 . Majority of the patients in both the age groups were in the age group of 21 to 25 years. Primigravida are more common in both

study group and control group constituting 55% of cases. In study group most cases is in between 34 weeks to 36 weeks 6days contributing of 80%. Most of the cases in study group falls in lower middle class of BG Prasad socioeconomic status constituting of 28%, however, in control group most of the cases falls in middle class (52%) followed by upper middle class (42%).

Most (62%) of the women had preterm vaginal delivery in study group, and in control group most (66%) of the women delivered by full term vaginal delivery. Majority of the baby in both study (58%) and control (52%) were male baby. The mean birth weight of the baby in study population is 2.1 kg with SD of 0.34 and in control group is 3.09 kg with SD of 3.09.

The p-value being <0.001, which is highly statistically significant. The mean APGAR score of the baby in study population is 6.58 with SD of 0.54 at 1 min and 8.56 with SD of 0.54 at 5 min, and in control group is 7 at 1 min and 9 at 8 min. The p-value being <0.001, which is highly statistically significant. In study group 38 % of the baby was admitted to NICU, however in control group none of the baby had required NICU admission. The mean serum magnesium level (mEq/L)in study population is 1.39 mEq/L with SD of 0.2 and in control group is 2.08 mEq/L with SD of 0.2 . The p-value being <0.001, which is highly statistically significant. The low level of mean serum magnesium is observed in lower middle class which is 1.29 with SD of 0.14 and in lower class is 1.28 with SD of 0.1. The p-value being 0.003 and 0.004 respectively which is statistically significant. The value of serum magnesium levels decrease with the increase in gestational age in both study and control group.

CONCLUSION: Serum magnesium levels in our study were significantly lower in those who delivered preterm when compared with those who delivered at term,

suggesting a possible role of hypomagnesemia in initiation of preterm labour. Larger studies are required to conclusively prove the role of hypomagnesemia in preterm labour.

INTRODUCTION

A decorative graphic consisting of a thick horizontal black line and a thick vertical black line intersecting at a right angle. The horizontal line extends from the left edge of the page towards the right, and the vertical line extends from the bottom edge of the page upwards. The intersection point is located to the right of the word 'INTRODUCTION'.

OBJECTIVES



REVIEW OF LITERATURE

A decorative graphic consisting of a thick horizontal line and a thick vertical line intersecting at the right end of the horizontal line, positioned below the title.

MATERIALS & METHODS

A decorative graphic consisting of a thick horizontal black line and a thick vertical black line intersecting at the right end of the horizontal line. The horizontal line starts under the 'M' of 'MATERIALS' and extends to the right edge of the page. The vertical line starts above the 'M' of 'MATERIALS' and extends downwards, crossing the horizontal line.

RESULTS

A decorative graphic consisting of a thick horizontal black line and a thick vertical black line intersecting at the right end of the horizontal line. The vertical line extends both above and below the horizontal line.

DISCUSSION

A decorative graphic consisting of a thick horizontal black line and a thick vertical black line intersecting at a right angle. The intersection is slightly offset from the bottom right corner of the page, creating a crosshair effect.

CONCLUSION

A decorative graphic consisting of a thick horizontal black line and a thick vertical black line intersecting at the right end of the horizontal line. The horizontal line extends from the left edge of the page towards the right, and the vertical line extends from the top edge of the page towards the bottom, crossing the horizontal line.

SUMMARY

A decorative graphic consisting of a thick horizontal black line and a thick vertical black line intersecting at a right angle. The horizontal line extends from the left edge of the page towards the right, and the vertical line extends from the bottom edge of the page upwards. The intersection point is located to the right of the word 'SUMMARY'.

BIBLIOGRAPHY

A decorative graphic consisting of a thick horizontal line and a thick vertical line intersecting at the right end of the horizontal line. The horizontal line is black and the vertical line is grey.

ANNEXURES



INTRODUCTION

Preterm labour is defined as labour occurs with regular and frequent uterine contractions causing progressive cervical changes before 37 completed weeks of gestation.¹ For the last 50 years, extensive research has been conducted with the objective of preventing, predicting and optimizing the outcome of patient with preterm labor.

WHO defines preterm labour as one where the labour starts before the 37 completed week (259 days) of gestation, counting from the first day of last menstrual period ¹. Incidence of preterm labour in India is about 5-10 % ². This leads to about 70- 80% of perinatal deaths². Late preterm (between 34 weeks and 0 days and 36 weeks and 6 days) accounts for about 74% of all preterm births, while the severe preterm birth (< 32 weeks) rate has remained relatively constant during the last two decades².

The causes of preterm labour is not yet completely known; in 50 % cases it is spontaneous and idiopathic ³. Some of the causes of preterm labour are PROM , multiple pregnancies, polyhydramnios, hypertensive disorders of pregnancy, infections, cervical incompetence, antepartum haemorrhage, fetal and uterine anomalies, anaemia, heavy work, smoking etc. it is also related to socioeconomic status and geographic location ⁴. To prevent preterm labour successfully the therapeutic approach should be to focus on the initial event of labour instead of attempting to inhibit the cascade of events culminating in preterm labour.

Besides varied etiology, preterm labour may be due to an alteration in basic biochemical function of body at cellular levels stating emphasis to trace elements of which magnesium, being one of them is a subject of interest now a days. Magnesium is the

second most plentiful positively charged ion found within the cells of body signifying its importance in various physiological cellular functions .

Serum levels of magnesium ranges from 1.6 to 2.6 mEq/dl in adults ⁴. Hypomagnesaemia leads to neuromuscular hyperexcitability resulting in muscle cramps and uterine hyperactivity. The hyperexcitability of uterine musculature induced by hypomagnesemia leads to increased cervical dilatation which in turn facilitates approach of vaginal microorganisms into cervical canal and changes quality and quantity of vaginal discharge while uterine passage is being colonised by pathogenic micro organisms⁵.

It is known that serum magnesium levels fall during pregnancy with gestational age⁶. This decrease serum magnesium play an important role in the physiology of parturition. Decrease of magnesium level in plasma may be responsible for decrease of same in myometrium leading to initiation of uterine contraction and labour^{7,8}.

The aim of this study is to determine the relationship between serum magnesium level and preterm delivery, so that the high morbidity and mortality related to prematurity could be reduced by early diagnosis of this deficiency and its correction.

AIMS AND OBJECTIVES OF THE STUDY

- ▶ 1.To estimate the serum magnesium levels in women with preterm labour.
- ▶ 2. To compare the value of serum magnesium levels in women with preterm labour with those women in the same gestational age who delivered at term.

REVIEW OF LITARATURE

A) CONCEPT OF PRETERM LABOUR:

The average duration of normal pregnancy is 267 days, counted after conception, or 280 days (40 weeks) from the first day of the last normal period. Infants born at 39 and 40 weeks of gestation have the lowest rates of adverse outcomes.

In the past, birth weight was taken as the parameter to differentiate between preterm and term infants. It is now understood that many factors beside gestational age affect birth weight.

Hence, gestational age is the only parameter used for diagnosis of preterm labor.⁹

Preterm labor is defined by WHO in 1969 that it is the initiation of regular painful uterine contractions that occurs usually with increasing frequency and intensity associated with progressive cervical changes of effacement and dilatation of cervix before 37 completed weeks of gestation from the first day of the last normal menstrual period.^{10,11} This definition, which has now been in use for almost 40 years, was first promulgated in 1969 by World Health Organisation (WHO) and International Federation of Gynecology and Obstetrics (FIGO).

Preterm birth (PTB) may be defined as birth between the age of viability and before 37 completed weeks of gestation⁵. In the Unitedkingdom, PTB includes deliveries between 24 weeks and 36 weeks and 6 days gestation and many developed and developing countries officially records all births with birth weight above 500g. The lower limit of this definition is less clearly defined it will be that gestational age though to correlate with fetal viability.¹² In USA, this is often taken as 20wks.

In Singapore, for legal purposes viability is defined as any gestation carried beyond 28

weeks, but fundamental to the issue of viability is the gestation at which the fetus is thought to be capable of being born alive and the capacity to sustain such life without undue morbidity and mortality.¹³

Threatened preterm labour is defined as pregnancies complicated by episodes of clinically significant uterine activity but without cervical change.¹⁴

Those born before 34 completed weeks of gestation are labeled as early preterm and those occurring between 34 completed weeks and 36 completed weeks are labeled as late preterm. Late preterm comprises of 74% of all the preterm births¹⁵.

Preterm can be categorise based on gestational age as :

1. Extremely preterm (<28 weeks)
2. Very preterm (28 to <32 weeks)
3. Moderate to late preterm (32 to <37 weeks)

Most recently, Spong (2013) observed¹⁶, “it has become apparent that infants born between 37 weeks 0 days and 38 weeks 6 days gestation experience morbidities that are associated with prematurity compared to births at 39 weeks 0 days through 40 weeks 6 days when infant mortality is lower than at any other time in human gestation.” Those births 37 weeks 6 days through 38 weeks 6 days are now defined as *early term* and those 39 weeks 0 days through 40 weeks 6 days are defined as *term*.

The American College of Obstetricians and Gynecologists (ACOG)¹⁷ and Society for Maternal-Fetal Medicine (SMFM) have adopted the nomenclature later preterm (34 weeks to 36 weeks 6 days of gestation) and early term (37 weeks to 38 weeks 6 days of

gestation) to acknowledge the contribution of gestational age in these ranges to neonatal risks.

Olsen IE, et al, (2013)¹⁸ defined “small for gestational age” (SGA), defined as weight less than 10th percentile at a given fetal gestational age. By this definition, less than 2,500 grams at birth is considered SGA. “Large for gestational age” (LGA) is defined as weight greater than the 90th percentile for duration of gestation. Infants greater than 4,500 grams at term birth are LGA. Low birth weight infants can be further classified into very low birth weight (VLBW) which includes infants less than 1500 grams and extremely low birth weight infants (ELBW) which are infants less than 1000 grams.

WHO (2013) ¹⁹ Viability is often defined as the gestational age at which there is a 50% chance of survival with or without medical care; therefore, under current conditions, viability in developed, high income countries of the world is somewhere between 22–24 weeks, whereas viability is closer to 34 weeks gestational age in low- and middle-income countries.

INCIDENCE:

Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation), and this number is rising. That is more than 1 in 10 babies.

Almost 1 million children die each year due to complications of preterm birth. Many survivors face a lifetime of disability, including learning disabilities and visual and hearing problems²⁰.

Globally, prematurity is the leading cause of death in children under the age of 5. And in

almost all countries with reliable data, preterm birth rates are increasing. Inequalities in survival rates around the world are stark. In low income settings, half of the babies born at or below 32 weeks (2 months early) die due to a lack of feasible, cost-effective care, such as warmth, breastfeeding support, and basic care for infections and breathing difficulties. In high-income countries, almost all of these babies survive²⁰.

The incidence of preterm birth range from 5% to 8% in most developed and developing countries but the incidence is increasing worldwide due to rise in multiple gestations from assisted reproductive techniques, better dating scans and iatrogenic deliveries .⁶

Incidence of preterm labour in India is about 5-10 % leading to 70-80% of perinatal deaths.²

About 0.75 million neonates die every year in India, the highest for any country in the world.

The neonatal mortality rate (NMR) declined from 52 per 1000 live births in 1990 to 28 per 1000 live births in 2013, but the rate of decline has been slow and lags behind that of infant and under-five child mortality rates²¹.

A systematic analysis of global, regional and national causes of child mortality in 2013 identified preterm birth complications and infections to be the two major causes of neonatal deaths in India.

A systematic analysis of global, regional and national causes of child mortality in 2013 identified preterm birth complications and infections to be the two major causes of neonatal deaths in India.²²(figure no.1)

The review, which included the data from the Million Death Study from India, found perinatal asphyxia and malformations to be the other two significant causes of neonatal

mortality. These findings are very similar to the overall global pattern²².

The data from three studies on the timing of neonatal deaths indicates that about three-fourths of total neonatal deaths occur in the first week of life.^{23,24,25} The first 24 hours account for more than one-third (36.9%) of the deaths that occur in the entire neonatal period.

The prospective study by Baqui et al.²³ provided data on the timing of cause-specific neonatal deaths: almost all deaths (97.8%) due to asphyxia occur in the first week of life, with 70% of them occurring within the first 24h (day 0).

About three-fourth of deaths due to prematurity (74.8%) occur in the first week of life, with 30% in the first 24h (day 0) to 50% of neonatal deaths secondary to sepsis occur in the first week of life. About 30% of sepsis-related deaths occur in the second week, whereas around one-fifth in weeks 3–4. Three-fourth of the deaths due to malformations occur in the first week of life, with day 0 alone contributing to nearly half of these deaths.

23




FIGURE NO.1. CAUSES OF NEONATAL DEATH IN INDIA.

The percentage of preterm births increased 36 percent from 9.4 percent in 1984 to a high of 12.8 percent in 2006 (Mathews, 2013)²⁶. Since 2006, however, the trend has reversed, and the percentage of preterm births declined to 11.7 percent in 2011 is decline in the percentage of preterm births occurred for both the early—less than 34 weeks—and later preterm periods (Hamilton, 2012)²⁷. Although the lowest level in more than a decade, the 2011 preterm birth rate is still higher than rates reported during the 1980s and most of the 1990s.

PATHOPHYSIOLOGY OF PRETERM LABOUR:

Term parturition and preterm parturition share anatomic, physiologic and biochemical features that are considered a common pathway of parturition. The pathway includes 1) cervical changes (softening and ripening), 2) membrane/ decidual activation, and 3) increased uterine contractility. Spontaneous labor at term results from physiologic activation of the common

pathway of parturition Whereas preterm labor is the result of a pathologic activation of this pathway.

Asynchrony can be clinically recognized as 1) cervical insufficiency when the process affects cervix predominantly; 2) preterm uterine contractions when the process affects the myometrium; or 3) preterm premature rupture of membrane (PPROM) if the insult acts on the chorioamniotic membrane.

Cervical changes occur over weeks, myometrial contractility is increased before the onset of labor, and appearance of fetal fibronectin (FFN) in the cervicovaginal mucus can be considered to reflect extracellular matrix (ECM) degradation, which indicates activation of the decidua and membranes.

A fetal maturity- based signal for labor originates in the fetal hypothalamus and leads to increased Secretion of corticotropin releasing hormone (CRH), which in turn stimulates adrenocorticotrophic Hormone (ACTH) and cortisol production by the fetal adrenals, which ultimately leads to activation of the common pathway of parturition. The fetus may contribute to spontaneous onset of preterm labor in the context of fetal inflammatory response syndrome.

Spontaneous PTB may be defined as a syndrome in which the clinical presentation of preterm labor, Preterm ruptured membrane and preterm cervical effacement and dilatation without labor occur as a result of multiple etiologies that can occur alone or in combination.

CERVICAL CHANGES: SOFTENING AND RIPENING:

The cervix is the main structure in pregnancy and parturition; it must maintain structural Integrity and acts as a physical barrier during pregnancy and subsequently transition to allow passage of the fetus during delivery. The change is not acute; physiological parturition occurs over the course of gestation and requires evolving biochemical and biomechanical changes in the cervix that manifest as cervical ripening.^{28,29.}

The 3 main structural components in the cervix of women are smooth muscle, collagen and the connective tissue ground substance containing glycosaminoglycans (GAGs). Smooth muscle content in the cervix is about 25%, 16% and 6% in the upper, middle and lower segments respectively.³⁰

Although collagen is the main contributor to the tensile strength of the cervix, GAGs are critical to determining the viscoelastic properties of the tissue. The GAGs are long, unbranched polysaccharides- vital components of the extracellular matrix(ECM).

Changes in ECM during cervical ripening includes an influx of inflammatory cells- macrophages, neutrophils, mast cells, eosinophils and so on- into the cervical stroma in a process similar to an inflammatory response. These cells produce cytokines and prostaglandins that affect ECM metabolism. Prostaglandins effect cervical ripening physiologically.

The primary factor for cervical ripening is the changes that take place in collagen and in connective tissue. The collagen fibrils which was previously arranged in an orderly fashion breaks up and the ground substances becomes prominent.

The cervical distensibility increase, while protein and collagen concentrations decline. This lost of collagen results in proteolytic digestion and subsequent elimination of the soluble collagen fragments.

Cervical changes normally precede the onset of labor, are gradual and develop over several weeks. PTB is often preceded by cervical ripening over a period of weeks in the second and third trimesters, evidenced on clinical examination by softening and thinning of the cervix.

ACTIN-MYOSIN INTERACTION:

Interaction of myosin and actin is essential to muscle contraction. This interaction requires that actin be converted from a globular to a filamentous form. Moreover, actin must be attached to the cytoskeleton at focal points in the cell membrane to allow development of tension.

Actin must partner with myosin, which is composed of multiple light and heavy chains. The interaction of myosin and actin activates adenosine triphosphatase (ATPase), hydrolyzes adenosine triphosphate, and generates force. This interaction is brought about by enzymatic phosphorylation of the 20-kDa light chain of myosin. This is catalyzed by the enzyme myosin light-chain kinase, which is activated by calcium. Calcium binds to calmodulin, a calcium-binding regulatory protein, which in turn binds to and activates myosin light-chain kinase.

Agents that promote contraction act on myometrial cells to increase intracellular cytosolic calcium concentration— $[Ca^{2+}]_i$. They allow an influx of extracellular calcium through ligand- or voltage-regulated calcium channels. For example, prostaglandin $F_{2\alpha}$ and oxytocin bind their respective receptors during labor to open ligand-activated calcium channels.

Activation of these receptors also releases calcium from the sarcoplasmic reticulum to cause decreased electronegativity within the cell. Voltage-gated ion channels open, additional calcium ions move into the cell, and cellular depolarization follows. This increase in $[Ca^{2+}]$ is often transient, but contractions can be prolonged through the inhibition of myosin phosphatase activity (Woodcock, 2004)³¹.

Conditions that decrease $[Ca]_i$ and increase intracellular concentrations of cyclic denosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP) ordinarily promote uterine relaxation.

In addition to myocyte contractility, myocyte excitability is also regulated by changes in the electrochemical potential gradient across the plasma membrane. Before labor, myocytes maintain a relatively high interior electronegativity. This state is maintained by the combined actions of the ATPase-driven sodium potassium pump and the large conductance voltage- and Ca^{2+} -sensitive K channel—maxi-K channel (Parkington, 2001)³².

During uterine quiescence, the maxi-K channel is open and allows potassium to leave the cell to maintain interior electronegativity. At the time of labor, changes in electronegativity lead to depolarization and contraction (Brainard, 2005; Chanrachakul, 2003)^{33,34}. And, as parturition progresses, there is increased synchronization of electrical uterine activity.




FIGURE NO. 2 . Uterine myocyte relaxation and contraction

A. Uterine relaxation is maintained by factors that increase myocyte cyclic adenosine monophosphate (cAMP). This activates protein kinase A (PKA) to promote phosphodiesterase activity with dephosphorylation of myosin light-chain kinase (MLCK). There are also processes that serve to maintain actin in a globular form, and thus to prevent fibril formation necessary for contractions.

B. Uterine contractions result from reversal of these sequences. Actin now assumes a fibrillar form, and calcium enters the cell to combine with calmodulin to form complexes. These complexes activate MLCK to bring about phosphorylation of the myosin light chains. This generates ATPase activity to cause sliding of myosin over the actin fibrils, which is a uterine contractor. AC = adenylyl cyclase; Ca^{++} = calcium; DAG = diacylglycerol; Gs and $G\alpha$ = G-receptor proteins; IP_3 = inositol triphosphate; LC20 = light chain 20; PIP_3 = phosphatidylinositol 3,4,5-triphosphate; PLC = phospholipase C; R-

PKA = inactive protein kinase. (Redrawn from Smith, 2007.)

RISK FACTORS ASSOCIATED WITH PRETERM LABOR:³⁰

MATERNAL CHARACTERISTICS NOT MODIFIABLE DURING PREGNANCY	RELATIVE RISK
Age<18yrs	1.5-3.4
Age>35yrs	1.3-1.8
Unmarried	2.2
Unemployed	2.3
Primigravida	1.9
Black women	-
MATERNAL CHARACTERISTICS MODIFIABLE DURING PREGNANCY	RELATIVE RISK
Low BMI(<20)	1.5-1.8
Cigarette smoking(>20/day)	1.3
Heavy work	2.1-3.3`
Stress(perceived)	1.2-1.8
Substance abuse	2.5-6.0
PAST REPRODUCTIVE HISTORY	RELATIVE RISK
2 Previous first trimester loss	2.9
2 Previous therapeutic terminations	2.5
Second trimester loss	4.2
One previous preterm delivery	2-5
Two previous preterm deliveries	4-7.6

The risk of preterm labor birth before 32 weeks was 1 in 10 if the previous preterm birth

was before 28wks, 1 in 15 if the previous preterm birth was 28 to 34weeks and 1 in 28 if it was between 35 to 36 weeks of gestation.

PREGNANCY COMPLICATIONS NOT AMENABLE TO INTERVENTION	RELATIVE RISK
Multiple pregnancies	-
Pre-existing maternal illness	-
Fetal malformation	-
Preeclampsia	-
First or second trimester bleeding	1.6-2.0

Assisted reproductive techniques like IVF and ovulation inducers increases multiple pregnancies, contributing 50% of twins being born preterm.

The acute maternal illness, especially systemic infection can precipitate labor. Fetal malformations like multiple anomalies, renal anomalies and anterior abdominal wall defect deliver preterm.

PREGNANCY COMPLICATIONS AMENABLE TO INTERVENTION	RELATIVE RISK
Asymptomatic bacteriuria	2-4
Bacterial vaginosis	1.4-1.8
Cervical incompetence	-
Uterine anomalies	-
STD's	-
SCREENING TESTS DURING PREGNANCY IN SELECTED PREGNANCIES	RELATIVE RISK
Cervical length<1 st centile	1.4
Cervical length5 th centile	9.5
Fetal fibronectin	7.5
Maternal plasma CRH in second trimester	3.5

ETIOLOGY OF PRETERM LABOR:

CERVICAL INSUFFICIENCY:

The cervix is a unique and complex structure with has a central role in maintaining the growing and developing embryo until term inside the uterine cavity.

The objective is achieved by remaining closed and non-compliant until the onset of labor at term. The cervix is therefore likely to play a very significant role in the etiology, prevention and treatment of preterm labor. In the non-pregnant state, the cervix consists of an extracellular connective tissue matrix made up of collagen, elastin, proteoglycans, a thin layer of smooth muscle and fibroblasts, which penetrate the connective tissue matrix.

During pregnancy, the cervix increases in water content, in mass and vascularity with a

reduction in collagen content as pregnancy advances which leads to cervical softening. If these changes occurred in early pregnancy, an 'insufficient cervix' will result.

'Cervical insufficiency' is defined as painless cervical effacement and dilatation leading to second trimester pregnancy loss or preterm delivery.³⁵ Cervical insufficiency occurs in upto 2% of all pregnancies, but responsible for only 8-9% of all preterm births compared to 40-50% from spontaneous preterm labor and 20-30% from preterm prelabor rupture of membranes (PPROM).^{36,37.}

Preterm labor has many causes which include:

1) Previous history:

There is a strong relationship between a history of prior preterm labor and short cervical length. Studies have reported that a strong correlation between cervical length in index pregnancy and previous obstetric history in a study which includes women with a history of cervical insufficiency (32 women) previous preterm delivery < 26 weeks (98 women), 27- 32 weeks(98 women), 33-35 weeks (127 women) and a control group of women with previous term delivery (106 women)³⁸

The gestational age of the first preterm delivery was significantly correlated with cervical length in the present pregnancy at each gestational interval between 20 weeks and 30 weeks in a continuous manner³⁸.

Guzman studies also found a strong relationship between previous obstetric history and cervical length in the subsequent pregnancy³⁹. Similarly, Andrews and coworkers found that those women who had history of spontaneous second-trimester miscarriage and preterm delivery due to cervical insufficiency had an increased risk of recurrence in a subsequent pregnancy^{40,41,42..}

Preterm delivery rates increases as the gestational age of the prior preterm decreased
(David F Colombo, 2000 ⁴³)

BIRTH OUTCOME	SECOND BIRTH <34WKS(%)
First birth>35wks	5
First birth<34wks	16
First and second births<34wks	41

2) Congenital abnormalities:

Female offspring's of women who took diethylstilbestrol (DES) were at increased risk of uterine anomalies with approximately 30% of these affecting the cervix⁴⁴.

3) Obstetrics trauma:

Cervical laceration or injury may occur during labour or delivery, that might includes spontaneous labour, forceps and vacuum delivery or caesarean section⁴⁵.

These factors may weaken the cervix and contribute to cervical insufficiency.

4) Cervical surgery:

Pregnant women giving history of cone biopsy, large loop excision of transformation zone (LLETZ) or laser ablation of the cervix are at increased risk of preterm birth⁴⁶. It is said that the risk was greater if the depth of excision was >10 mm compared to excision depths of <10mm.⁴⁷

Laser vaporization, cryotherapy and punch biopsy are associated with preterm birth⁴⁸

5) Uterine over-distension:

Multiple pregnancies and polyhydramious also carry an increased risk of preterm labor. About 40% of twin pregnancies will have spontaneous preterm labour or pPROM. Women with multiple gestations has been shown to be more likely to have short cervix at 24 weeks, which is probably due to a rapidly expanding uterus putting extra pressure on the cervix.⁴⁹

In Multiple pregnancy and in polyhydramnios it is likely that early uterine distension acts to initiate expression of contraction associated proteins (CAPS) in the myometrium. The CAP genes influenced by stretch include those coding for gap junction proteins such as connexin 43, for oxytocin receptors and for prostaglandin synthesis resulting of excessive uterine stretch is the premature loss of myometrial quiescence.⁵⁰

Uterine stretch also exhibits an early activation of the placental fetal endocrine cascade resulting in an early rise in maternal CRH and oestrogen levels, which can further enhance the expression of myometrial CAP genes.⁵¹

6) Multiple dilatation and evacuation:

The Aggressive and forceful dilatation of the cervix during surgical termination of pregnancy may in some women leads to cervical damage. Studies have shown that two or more prior dilatation and evacuation especially for late termination of pregnancy is associated with increased risk of cervical insufficiency and preterm labour⁵².

Therefore RCOG recommends the use of cervical ripening agents such as vaginal misoprostol prior to the procedure⁵³.

7) Infection:

Infection may have a casual or effect relationship with cervical insufficiency. Some proportion of women with cervical insufficiency in the second trimester have microbial invasion of amniotic cavity (MIAC)^{54,55}.

It is caused by premature cervical dilatation with exposure of chorioamniotic membranes to the microbial flora of lower genital tract.

Intrauterine infection can either be from the ascending or haematogenous route in the second trimester of pregnancy may produce cervical ripening and dilatation, and uterine contractions⁵⁶. These contractions are usually silent in the mid-trimester and the clinical conditions may be indistinguishable from that of an incompetent cervix.⁵⁷

The presence of abnormal vaginal flora such as bacterial vaginosis or intermediate flora is associated with an increases risk of late miscarriages and early preterm delivery and in women with a short cervix^{58,59}. Other infections which can implicate in preterm births includes chlamydia, Group B streptococcus, mycoplasma and gonorrhea.

Sources of intrauterine infection:

Bacteria can gain access to the intrauterine tissues through

- . 1) Trans placental transfer of maternal systemic infection.
- . 2) Retrograde flow of infection from the peritoneal cavity via the fallopian tubes.
- . 3) Ascending infection from the vagina and cervix is considered the most common.
- . Intra uterine infection is categorized into 4 stages of microbial invasion that includes
 - 1) Bacterial vaginosis (stage 1)
 - 2) Decidual infection (stage 2)

3) Amniotic infection (stage 3)

4) Fetal systemic infection(stage 4)

Progression of these stages is throughout to increase the effects on preterm birth as well as neonatal morbidity.⁶⁰

MECHANISM CAUSING INFECTION INDUCED PRETERM LABOR




FIGURE NO. 3. MECHANISM OF INFECTION INDUCED PRETERM LABOR.

TESTS TO DETECT THE INFECTION:

No tests are available to diagnose the earlier stage of infection, but test to detect the advanced stages of infection are available.

-
- 1) Amniotic fluid gram stain has got 100% positive predictive value.⁶¹
 - 2) Limulus gametocyte lysate assay: This test is used for the detection of gram-negative endotoxin and also certain gram positive intra amniotic infection. The sensitivity of this test when combined with gram stain is 95%.⁶²
 - 3) Gas liquid chromatography: This test identifies fatty acid chains elaborated by microbial metabolism. The sensitivity is high. The test is very expensive.⁶³
 - 4) Bacterial cultures: This provides definite evidence of the presence of amniotic fluid infection.⁶⁴
 - 5) Presence of leucocytes in the amniotic fluid is a relatively insensitive test. Leucocytosis in the absence of bacteria may suggest the possibility of Mycoplasma infection.
 - 6) Acridine orange stain allows visualization of Mycoplasma in the amniotic fluid with leucocytosis and without bacteria seen in the gram stain.
 - 7) Histologic examination of the placenta which can be done post partum.

Extra Uterine Infection:

5 to 10% of patients in preterm labor have an infection outside the uterus, most common is culture proven UTI, other like pyelonephritis, Malaria, pneumonia, tuberculosis and periodontal infection.

- 8) Preterm prelabour rupture of membranes(pPROM):pPROM is defined as the spontaneous rupture of fetal membranes prior to the onset of labour and before 37 weeks of gestation. pPROM complicates about 2% of pregnancies and occurs

in 14,000 pregnancies in UK and 150,000 pregnancies in the US, which accounts for 30% of preterm deliveries ⁶⁵.

It is also associated with significant maternal risks including chorioamnionitis with serious systemic infection and neonatal morbidity and mortality including prematurity, sepsis and pulmonary hypoplasia ^{66,67}.

Studies have shown that women with pPROM have positive amniotic fluid culture in a third of pregnancies following amniocentesis ^{68,69}. Women with intrauterine infection have a shorter latency period than non-infected women and babies usually born with sepsis leading to four-fold increase in mortality rate compared with babies without sepsis. ⁷⁰

9) Connective tissue disorders:

Certain connective tissue disorders such as Ehlers-Danlos Marfan syndrome have been implicated in the aetiology of preterm birth ⁷¹. It is characterized by disorganization of collagen fibrils in the cervix causing cervical incompetence and preterm labour ⁷².

10) Placental abnormalities:

Battledore placenta, circumvallate placenta and Marginal insertion of the Umbilical cord, placenta previa, abruptio placenta and placental vascular insufficiency all lead to preterm labor.

11) Fetal pathology:

Neural tube defects and inborn errors of metabolism like; Hyperalaninemia and potters

syndrome are found to be associated with preterm labor.

12) Assisted reproductive technique:

Preterm labor delivery occurs more commonly in pregnancies conceived after ovulation inducers and assisted reproductive technologies such as IVF, GIFT, ART pregnancies contributed 22% of all high order multiple gestation and 40% following super ovulation.

IMPLICATIONS OF PRETERM BIRTH:

Preterm birth is the leading cause of neonatal morbidity and mortality worldwide and accounting for 75% of neonatal deaths and 50% of long term morbidity, including respiratory diseases and neurodevelopment impairment ⁷³.

The risk of morbidity and mortality are inversely related to the gestational age at birth. The EPICure study in the United Kingdom and Ireland ⁷⁴ assessed survival trends and health outcomes in infants who are born in less than or equals to 26 completed weeks (20 weeks to 25 weeks and 6 days) over a period of 10 months in 1995. This study showed increased survival and reduced rate of severe disability with each additional week of intrauterine gestation.

They have also reported that 50% of survivors at 23-25 weeks gestation were impaired, half with severe disability ⁷⁴.

In another study the Epipage study also recruited babies born in nine French regions during 1997 and Trent health region study also produced similar results on rates of survival and Discharge ^{75,76}.

The EPICure two study has been collected data on all babies born in England in 2006 between 22 and 26 weeks 6 days gestation⁷⁷. There was an improved survival of these babies by 13 % (40-53%) and was more at 24 weeks and 25 weeks. They also found that the care which has provided to these mothers have improved but the number of babies discharge from hospital with disabilities such as abnormal brain scans, lung, bowel and eye problems are very similar to the findings of EPICure in 1995.

Studies show that preterm birth carries significant social and economic burden which is estimated to cost the public sector of 2.9 billion euro a year⁵⁴. The total cost of preterm birth estimated by Khan and coworkers was 15,688 euro for upto 34 weeks and 12,104 euro for upto 37 weeks⁷⁸.

Severe morbidity such as intraventricular hemorrhage (IVH), Respiratory Distress syndrome (RDS), bronchopulmonary dysplasia (BPD), Necrotising Enterocolitis (NEC) is common before 28 weeks and extends into 30-32 weeks Range.

Tracy A. MANUCK , et al, studied a secondary analysis of an obstetric cohort of 115,502 women and their neonates who were born in 25 hospitals nationwide, 2008–2011⁷⁹. All live born non-anomalous singleton preterm (23.0–36.9 weeks of gestation) neonates were included in this analysis. The frequency of neonatal death, major neonatal morbidity (intraventricular hemorrhage grade III/IV, seizures, hypoxic-ischemic encephalopathy, necrotizing enterocolitis stageII/III, bronchopulmonary dysplasia, persistent pulmonary hypertension), and minor neonatal morbidity (hypotension requiring treatment, intraventricular hemorrhage grade 1/2, necrotizing enterocolitis stage 1, respiratory distress syndrome, hyperbilirubinemia requiring treatment) were calculated by deliver

gestational age; each neonate was classified once by the worst outcome they met criteria for. Major morbidity includes persistent pulmonary hypertension, intraventricular hemorrhage grade 3/4, seizures, hypoxic-ischemic encephalopathy, necrotizing enterocolitis stage II/III, bronchopulmonary dysplasia minor morbidity includes intraventricular hemorrhage grade 1/2, necrotizing enterocolitis stage 1, RDS, hyperbilirubinemia requiring treatment, hypotension requiring treatment.

Table.1. Frequency of death and major, intermediate and minor morbidity. Data are n(%)⁷⁹.

Delivery gestational age	death	Major morbidity	Minor morbidity	Survival without any of the above morbidities
All (n=83334)	119(1.4)	657(7.9)	3136(37.6)	4422(53.1)
23(n=43)	19(42.2)	19(42.2)	4(9.3)	1(2.3)
24(n=114)	36(31.6)	60(52.6)	18(15.8)	0(0.0)
25(n=124)	15(12.1)	68(54.8)	39(31.5)	2(1.6)
26(n=169)	19(11.2)	88(52.1)	59(34.9)	3(1.8)
27(n=159)	13(8.2)	64(40.3)	77(48.4)	5(3.1)
28(n=196)	4(2.0)	43(21.9)	144(73.5)	5(2.6)
29(n=213)	4(1.9)	48(22.5)	147(69.0)	14(6.6)
30(n=262)	4(1.5)	36(13.7)	206(78.6)	16(6.1)
31(n=312)	3(1.0)	22(7.1)	255(81.7)	32(10.3)
32(n=451)	1(0.2)	39(8.7)	344(76.3)	67(14.9)
33(n=639)	1(0.2)	27(4.2)	406(63.5)	205(32.1)
34(n=1058)	0	46(4.4)	540(51.0)	472(44.6)
35(n=1477)	0	42(2.8)	402(27.2)	1033(69.9)
36(n=3117)	0	55(1.8)	495(15.9)	2567(82.4)
P for trend	<0.001	<0.001	<0.001	

Threshold of Viability

Births *before* 26 weeks are generally considered the current threshold of viability. The preterm infants pose various complex medical, social, and ethical considerations.

Infants now considered to be at the threshold of viability are those born at 22, 23, 24, or 25 weeks (American College of Obstetricians and Gynecologists, 2012) ⁸⁰.

The infants have been described as fragile and vulnerable because of their immature organ systems. Moreover, they are at high risk for brain injury from hypoxic-ischemic injury and sepsis. In this setting, hypoxia and sepsis start a cascade of events that lead to brain hemorrhage, white-matter injury that causes periventricular leukomalacia, and poor subsequent brain growth eventuating in neurodevelopmental impairment.

Because active brain development normally occurs throughout the second and third trimesters, those infants born at 22 to 25 weeks are believed especially vulnerable to brain injury ⁸¹.

The most recent report from the United States concerning survival and morbidity rates for births at 22 to 26 weeks is from the National Institute of Child Health and Human Development (NICHD) Neonatal Network ⁸².

This dataset includes 5736 live births delivered between 2003 and 2007 at 20 medical centers across the United States⁸². Rates of survival and survival without morbidity in the neonatal period are shown in the table below.

outcome	22 weeks	23 weeks	24 weeks	25 weeks	26 weeks
Live infants	421	871	1370	1498	1576
Survived to discharge(%)	6	26	55	72	84
Percentage with no chronic morbidity	0	8	9	20	34

TABLE NO. 2. SURVIVAL AND DISABILITY RATES FOR 5736 LIVE BIRTHS BORN BETWEEN 22 WEEKS AND 26 WEEKS GEATATION AT 20 MEDICAL CENTRES IN THE UNTED STATES DURING 2003 TO 2007.

PREDICTION OF PRETERMBIRTH:

The three main lines of research in the prediction of the preterm labor.

- 1) Risk scoring system
- 2) Biochemical methods
- 3) Biophysical methods

RISK SCORING SYSTEM:

In 1984 Papiernik organized several factors associated with preterm labour into a high risk scoring system and this was slightly modified by **Gonik and Creasy in 1986.**

Point	Socio-economic Factors	Previous medical and Obstetric History	Daily habits	Aspects of Current Pregnancy
1.	Two children at home low socio- economic status	Abortion x 1 Less than 1 year Since last birth	Works outside	Unusual fatigue
2.	Maternal age<20 Years or>40years Single parent	Abortion x2	Smokes>10 Cigarettes/day More than 3 flights of stairs without elevator	Gain of <5k by 32 weeks
3.	Very low Socioeconomic status Height < 150 cms Weight < 45 kg	Abortion x 3	Heavy or stressful Work that is long and tiring Long daily commuting extensive travelling	Breech at 32 weeks Weight loss Head engaged at 32
4.	Maternal age<18 Years			Bleeding after 12 weeks Short cervix Opened internal os Uterine irritability

5.		Uterine anomaly Second-trimester Abortion DES exposure Cone biopsy		Placenta previa Hydramnios
6.		Preterm delivery Repeated second Trimester abortions		Twins Abdominal surgical Procedure

The patient with score of 10 or more in the papiernik scoring system is classified as being at high risk for preterm labor.

It gives a sensitivity of only 40% and a false positive rate of almost 80% reason may be multifactorial nature of disease and these mostly rely on past obstetric history and are inappropriate in nulliparous women.⁸³

BIOCHEMICAL MARKERS:

Cervical length screening and various biochemical markers like cervico vaginal cytokines (IL 1, TNF) and proteases, fibronectin, serum CRH and Estriol have been primarily investigated as potential predictive or diagnostic markers of preterm labor. They are

- 1) Fetal fibronectin (FFN)
- 2) Salivary Estriol

1) Fetal fibronectin:

It is a glycoprotein that is secreted by fetal membrane and help attach the chorion to the decidua. Fetal fibronectin thus acts like a 'glue' binding the choriodecidual membranes. Its presence in the cervicovaginal secretion, placenta and amniotic fluid is normal up to the 20th week.

It is rarely present in vaginal secretions between 23 weeks to 34 weeks of gestation. The test is performed at bedside and proper technique is required for the correct results.

Digital examination of the cervix should not be performed prior to this test and no lubricating gel should be used. The test is considered to be positive when fetal fibronectin is greater than 50ng/ml⁸⁴.

Studies have evaluated the role of fetal fibronectin test both in asymptomatic high- risk women and women in preterm labor. A positive test is associated with an increased likelihood of birth before 34 weeks gestation with 14 days of the test with the positive predictive value of 16% ⁸⁵.

In the negative test the risk of preterm delivery is < 1% within 14 days of the test.

There are two mechanisms may explain the presence of FFN in vaginal secretions in cases of spontaneous preterm labor. ⁸⁶

1. Separation of the chorion from the deciduous membrane of the lower uterine segment may allow its release.
2. FFN may be secreted in the cervical canal in response to chorionic inflammation.

50 ng/ml is used as a cut off value for a positive determination. Disadvantage is that the results are not available for several hours. Positive fetal fibronectin yields 90% sensitivity and 72% specificity. Negative fetal fibronectin has 94% negative predictive. Factors which increase the false positive are PROM, vaginal bleeding and where as vaginal lubricants and disinfectants increases the false negatives. There is a significant data to support the use of fetal fibronectin in evaluating preterm labor.

2) Estriol

Estriol begins to appear during the 9th week of pregnancy and its plasma concentration to increase through out the course. It have been shown to directly affect myometrial contractility, modulate the excitability of myometrial cells and increase uterine sensitivity to oxytocin.

There is surge in estradiol level within 2-4 weeks prior to the onset of labour⁸⁷. The estriol concentration in saliva very precisely reflects the free estriol concentration in plasma.

Cut off value 2 – 3ng/ml for predicting those women at risk of preterm labor and delivery with a sensitivity of 71% and specificity 77%, positive predictive value of 23%.

Administration of corticosteroids and dietary factors, which increases the false negatives.

This test can be used in asymptomatic population because it is a simple, reliable and stable test.⁸⁸

	SINGLE POSITIVE TEST	SECOND POSITIVE TEST
with in a week	23%	70%
with in 2weeks	54%	90%
with in 3weeks	85%	100

Others Biochemical markers:

Several biochemical markers have been evaluated for association with preterm labour like activin, inhibin and relaxin⁸⁹, but they all require further evaluation.

Elevated levels of b hCG and AFP have been noted, either individually or in combination to be associated with a increased risk of preterm delivery and also adverse pregnancy outcomes.⁹⁰

1) OTHER BIOCHEMICAL MARKERS: Mediators of inflammatory process
have not shown any promise as screening tests.

Amniotic fluid cytokines predicted preterm birth; IL 8 shows a sensitivity of 91% and a specificity of 87%. The high level of IL 18 in the cord blood of preterm infants is associated with neonatal development of periventricular leukomalacia and cerebral palsy.⁹¹

Ideally screening and treating lower genital tract and sexually transmitted infection is recommended prior to and in the first trimester of pregnancy.

Bacterial vaginosis is caused by anaerobic bacterial like *Gardeneralla vaginalis*, *Mobiluncus* species and *Mycoplasma hominis*. It is associated with spontaneous abortion, preterm labor and premature rupture of membrane, chorioamnionitis and amniotic fluid infection⁹².

Bacterial vaginosis is the only infectious marker that are being used as primary predictor in an unselected population. The higher risks of bacterial vaginosis are reported when

screening has been performed seven fold before 16wks and fourfold before 20wks of gestation. The use of inflammatory markers in current practice is limited because of lack of simplicity, medicare reproducibility and high cost, all issue as fundamental in daily practice as their capacity to identify preterm birth due to infection.

Some studies have found the association between Trichomonas infection and preterm birth⁹³. But there are certain others studies which could not provide such association and hence currently the screening and treatment for chlamydia or trichomonas to prevent preterm birth in women is not recommended⁹⁴.

Asymptomatic bacteriuria has been linked to preterm birth. Screening and treatment of asymptomatic bacteriuria in pregnancy have become standard practice in obstetrics care. Group B streptococcal (GBS) has been linked with preterm births, therefore it is recommended to the women at risk of preterm delivery to screen for GBS antenatally which allows intravenous antibiotics at the time of labor. Screening can be done by combined lower vaginal and rectal swab.

2) Plasma CRH:

Plasma CRH is a peptide produced by the syncytiotrophoblast and the fetal membranes is implicated in the initiation of labor. Its highest production of CRH levels is seen during the 3rd trimester.

PGE2 and F2 production from placenta and fetal membranes are regulated by CRH, and it potentiates the action of oxytocin. Sensitivity of the test is 24-73% Women at high risk for preterm labour have higher CRH levels when compared with women at low risk⁹⁵. The clinical use of CRH is doubtful in those cases which are associated with infections

and in cases of recurrent preterm labor.

3) HCG:

When there is abnormal placentation or disruption in the integrity of the choriodecidual interface shows the increased level of HCG in the maternal serum.

If > 32miu/ml to predict the delivery within 7 days it has positive predictive of 89% and negative predictive value of 95%.⁹⁶

4) Serum AFP has been suggested but sensitivity is poor.

5) Plasma granulocyte stimulating factors levels with odds ratio between 4-10 for delivery within a 4 weeks period after the test.

6) Cervical lactoferrin and sialidase values are related to preterm labor but sensitivities are low.

7) Role Of Thrombin: The presence of thrombin antithrombin levels of 8ng/ml had a positive predictive value of 80% for delivery within 3wks of positive test.⁹⁷

8) Recent markers include maternal serum collagenase, serum ferritin, and placental alkaline phosphatase. However, the routine use of these markers cannot be considered until convincing studies are available.

BIOPHYSICAL METHODS:

1) Uterine activity monitoring

2) Cervical assessment.

Uterine activity monitoring for the early diagnosis of preterm labor has been explain by four study methodology.

-
- 1) Maternal self-detection of uterine activity is significantly less likely to identify the crescendo in uterine activity.
 - 2) Perinatal nurses support the educational compartment by systematically questioning the patients regarding signs and symptoms of preterm labor and their subjective uterine contraction frequency based on self-palpation and to assess the patient's compliance with physician directed therapies or restrictions.
 - 3) HUAM: This is a device which was first used by Katz and colleagues in 1986 at San Francisco in a woman who was at high risk for preterm labor. When there is persistent uterine contractions at a frequency of >3/hr between 26-28 weeks, >4/hr between 28-30wks, >5/hr between 30-32 weeks predicted 80% of preterm births.
 - 4) The simultaneous assessment of an individual patient's signs and symptoms during the daily perinatal nursing telephone call along with objective uterine activity monitoring complemented by 24hrs/day, 7days/week availability of obstetrician are believed to be critical factors in the early diagnosis of preterm labor.⁹⁸
 - 5) UTERINE ELECTROMYOGRAPHY (EMG): The amount to the acquisition of uterine electrical signals can be taken noninvasively from the abdominal surface could benefit obstetricians when utilized as an everyday tool in the antenatal and labor wards to monitor uterine electrical recording in normal pregnancies and to diagnose or even predict abnormal conditions like preterm labor, in sufficient labor progress and dystocia.⁹⁹

CEVICAL ASSESSMENT:

The precocious cervical ripening and dilatation of the internal os of the cervix increase the risk of preterm delivery.

Papiernik in France has observed early cervical ripening was noted in 30% of pregnancies.

There was dilatation of the internal os was associated with fourfold increased risk of preterm delivery. The positive value for abnormal cervical findings are disappointingly low at 25 – 30% for high risk group and 4% for the low risk group and cervical dilatation of more than 2 cm predicts preterm delivery with a sensitivity of 60%.¹⁰⁰

Cervical length is a good predictor of PTB particularly in high risk women like those who had prior PTB¹⁰¹. It has been observed a positive predictive value of 70% and a sensitivity of 60-80% with a transcervical ultrasound cervical length (TVS CL) of less than 25mm between 14 and 18 weeks gestation⁴⁷.

There was only 4% risk of delivering preterm in high-risk women with normal cervical measurement between 14 and 18 weeks⁶⁵. It has been found that TVS CL is a positive predictive of PTB in other high risk women including women with prior cone biopsy, prior multiple dilatation and evacuation and mullerian anomalies¹⁰².

Women with uterine anomaly and short cervix on TVS have 13 fold increase in spontaneous PTB and those who have unicornuate uterus have the highest rate of PTB.

Skentou and coworkers found a TVS CL less than 2cm to have a 100% predictive value for PTB before 28 weeks gestation¹⁰³. Similarly other studies have also found cervical

length of less than 2.5cm at 24 weeks gestation to be a strong predictive factor for preterm labour⁴⁹.

Guzman and co-workers have found TVS CL to be a positive predictive factor of PTB in triplet pregnancies⁴⁹. Women with multiple gestations have been shown to be more likely to have short cervix at 24 weeks which may be due to rapidly expanding uterus exerting extra pressure on the cervix and not particularly due to cervical incompetent.

The cervical length measured at mean gestational age 28-31wks, optimal cut off value varies from 1.8-3 cm. Cut off value of 30 mm has sufficient sensitivity of 70-100%, if >30mm, negative predictive value of 100% in between 34-37wks.

Only cervical length (CL) has significant predictive accuracy but not the funneling (>5mm) because measurement incorporating funnel length to be less responsible and so less clinically useful.

Translabial ultrasound has recently been advocated for evaluation of cervix with the advantage of avoiding vaginal instrumentation compared to transvaginal ultrasound.

FLUORESCENCE SPECTROSCOPY:

It is a widely used research tool in biosciences to examine the collagen content of a variety of tissues including some cancers, now they are using this to evaluate the cervix.

The Cervical light induced fluorescence (LIF) is obtained noninvasively using an instrument **collascope**. Cervical LIF values decrease significantly as gestational age increases and are predictive of delivery within 24 hrs.¹⁰⁴

PREDICTORS OF RISK OF PRETERM LABOUR:¹⁰⁵

IN NULLIPAROUS WOMEN

	Delivery<32 wks	Delivery <35wks	Delivery <37wks
Both tests negative	0.6%	1.7%	6.0%
CL <25mm	3.7%	9.2%	18.4%
FFN positive	3.9%	5.8%	11.5%
Both tests positive	35.3%	58.8%	64.7%

IN MULTIPAROUS WOMEN ALONG WITH OR WITHOUT SPONTANEOUS

PRETERM BIRTH (SPB).¹⁰⁵

	Delivery<32wks	Delivery<35wks	Delivery<37wks
All markers are negative	0.5%	1.5%	7.3%
Previous SPB alone	1.8%	8.6%	17.6%
Previous SPB&CL <25mm	8.3%	29.2%	35.4%
Previous SPB&FFN Positive	24.0%	40.0%	48.0%
All markers are positive	50.0%	60.0%	60.0%

THE DAIGNOSIS OF PRETERM LABOUR

1) Uterine Contractions

The main symptom of preterm labor is uterine contractions. They should occur regularly, four or more in 20 minutes or eight or more in 1 hour, and each should last more than 40 seconds.

The perception of the frequency, intensity, and duration of contractions by different health care providers is frequently inaccurate and the best objective way to determine the frequency and duration of the contractions is by external monitoring with a tocodynamometer.

2) Digital Pelvic Examination

This examination the obstetrician should assess the position, length, consistency, and dilatation of the cervix, as well as the development of the lower uterine segment. The two more important variables to assess clinically are the length (effacement) and the dilatation of the cervix.

An important part of the digital examination of the women in preterm labor is the assessment of the lower uterine segment. All pregnant women regardless of their parity or gestational age stretch or develop their lower uterine segment before parturition. When the lower uterine segment is not developed, it is possible to introduce easily the fingers into the vaginal fornices. In contrast, when the lower uterine segment is developed, the examiner finds that the upper third of the vagina is filled with the thinned lower uterine segment.




FIGURE NO. 4 . DIAGNOSIS OF PRETERM LABOR

B) MAGNESIUM

Magnesium is the fourth most abundant cation in the body and the second most prevalent intracellular cation. The total body magnesium content is approximately 25 gms (1.03 mol), of which about 55% resides in the skeletal magnesium is exchangeable and is thought to serve as a reservoir for maintaining extracellular magnesium concentration. About 45% of magnesium is intracellular.

Drug was first used by Steer and Petrie as a tocolytic and later refined by Elliot in early 1970. It ranks as the tocolytic of choice by most of obstetricians in United States.

BIOCHEMISTRY AND PHYSIOLOGY:

The concentration of magnesium in cells is approximately 1 to 3 mmol/L (2.4 to 7.3 mg/dl). In general higher the metabolic activity of the cell, higher is its magnesium content. Within the cells most of the magnesium is bound to proteins and negatively charged molecules; 80% of cytosolic magnesium is bound to ATP and Mg ATP is the substrate for numerous enzymes.

The nucleus, mitochondria and endoplasmic reticulum content significant amount of magnesium. Approximately 0.5% to 5.0% of the total cellular membrane is regulated by a specific magnesium transport system. Extracellular magnesium accounts for about 1% of the total body content.

About 55% of magnesium is free, 30% is associated with proteins (primarily albumin), and 15% is complexed with phosphate, citrate and other anions.

Magnesium is the cofactor for more than 300 enzymes in the body. It is required for enzymes formation (for example, MgATP). In addition, magnesium is an allosteric

activator of many enzymes systems.

Examples of enzymes that require magnesium for action includes adenylate cyclase, Na K adenosine triphosphate (ATPase), Ca ATPase, phosphofructokinase, and creatine kinase.

The guanine nucleotide regulatory proteins Gs and Gi require magnesium for activity.

Magnesium is important in oxidative phosphorylation, glycolysis, cell replication, nucleotide metabolism and protein biosynthesis.

Serum levels between 5-8 mg/dl of MgSO₄ are needed to attain myometrial inhibition.

Magnesium is excreted by kidneys at a very high rate (90%) is cleared with in 24hrs.¹⁰⁶

Reducing the serum magnesium concentration decreases the threshold of axonal stimulation and increases the release of neurotransmitter at the neuromuscular junction by competitively inhibiting the entry of calcium in the presynaptic nerve terminal. Reducing the serum magnesium concentration results in increased neuromuscular excitability.

Assessment of magnesium levels:

The most common test done is the estimation of serum magnesium concentration. The other available test are estimation of ultrafiltrable Mg, Mg content of RBC's, mononuclear cells, metabolic tests like 24 hours urinary excretion of magnesium, Mg loading test, estimation of intracellular free magnesium ion concentration, etc. Serum magnesium can be measured by a variety of techniques. Serum magnesium is preferable to plasma as the anticoagulant in the vacuette could be contaminated with magnesium or

can directly interfere with assay. For instance, citrate binds not only calcium but also magnesium and affects fluorometric and colorimetric procedures.

Haemolysis, bilirubin, lipaemia, high phosphate concentration and delay in Separating serum can affect the measurement.

In adult serum magnesium concentration is not affected by sex or age except in the very elderly where it may be slightly higher. Serum magnesium concentration is lower during the third trimester of pregnancy.

The total serum magnesium concentration is not the best method to evaluate magnesium status as changes in serum protein concentrations may affect the total concentration without necessarily affecting the ionized fraction or total body magnesium status. The correlation between total magnesium and total body magnesium status is poor.

Serum magnesium is measured by different methods; viz;

1. Photometric methods
2. Atomic absorption spectrometry
3. Flame emission
4. Fluorometric methods

CAUSES OF HYPOMAGNESEMIA:

- 1) Redistribution of magnesium
 - a) Insulin therapy
 - b) Hungry bone syndrome

-
- c) Correction of acidosis
 - d) Catecholamine excess
 - e) Massive blood transfusion

2) Gastrointestinal causes

a) Reduced intake

Mg free intravenous fluids

Dietary deficiency

Low oxalate diet

Cellulose phosphate

b) Reduced absorption

Malabsorption syndrome

Chronic diarrhoea

Intestinal resection

Primary infantile hypomagnesaemia

3) Renal loss

Reduced sodium reabsorption

Saline infusion

Diuretics

4) Renal disease

Post obstructive nephropathy

Post renal transplantation

Dialysis

Diuretic phase of acute renal failure

Inherited disorders

Bartter's syndrome

Gitelman's syndrome

5) Endocrine causes

a) Hypercalcaemia

Primary

Malignant

b) Hyperthyroidism

c) Hyperaldosteronism

6) Diabetes mellitus

7) Alcoholism

8) Drugs

Diuretics

Cytotoxic drugs; cisplatin, carboplatin, gallium nitrate

Antimicrobial agents

Aminoglycosides; gentamycin, tobramycin, amikacin

Antituberculous drugs; viomycin, capreomycin

Immunosuppressants; cyclosporine, ritrodine

Beta adrenergic agonist: theophylline, salbutamol, reniterol

Others drugs; amphotericin B, pentamidine, Foscarne

pamidronate, anascrine.

HYPOMAGNESEMIA IN PREGNANCY

Pregnancy is a state of marked hypomagnesemia. Kruzel RB and co-workers have shown that the serum magnesium level has no gestational dependence (mean 1.79 ± 0.44 mg/dl) until 33 weeks of gestation, at which point it continuously declines¹⁰⁷.

In another study which was conducted in India with 150 patients by Agarwal U et al showed that the mean serum magnesium level in non-pregnant group, 1st trimester, 2nd trimester, 3rd trimester were found to be 2.31 ± 0.39 mg/dl, 2.20 ± 0.26 mg/dl, 1.49 ± 0.63 mg/dl and 1.07 ± 0.39 mg/dl respectively¹⁰⁸.

Therefore, the study have observed that magnesium level is lower in pregnancy and in pregnancy there was a significant fall in serum magnesium level in third trimester.

Kamal S et al have shown that the mean magnesium level is $2.2 \text{ mg}\% \pm 0.33$ S.D. in non pregnant women and $1.9 \text{ mg}\% \pm 0.3$ S.D in normal pregnant women¹⁰⁹.

Other study have concluded that pregnancy is a state of extracellular magnesium depletion and diabetes in pregnancy exaggerates this deficiency¹¹⁰.

Hypomagnesemia in pregnancy can be due to hemodilution associated with pregnancy. The increase in renal clearance during pregnancy may contribute to reduction in serum magnesium. The other factors leading to hypomagnesemia in pregnancy may be poor dietary intake and consumption of minerals by growing fetal skeletal system¹¹¹.

Studies have found that another important cause for markedly increased magnesium in

pregnancy loss is due to routine calcium supplementation at 1.5g/day¹¹².

Cunze T et al conclude that magnesium level in the plasma correlates with magnesium in the myometrium and hence hypomagnesemia during pregnancy decrease the magnesium in the myometrium¹¹³.

HYPOMAGNESEMIA AND PRETERM LABOUR

The pathophysiology of the labor have described a central role of calcium in initiation of uterine contraction. Phillippe M have conducted a study to test the hypothesis that magnesium inhibits extracellular calcium entry¹¹⁴. He performed in vitro studies using uterotonic agents like oxytocin, which produced cystolic calcium oscillations and simultaneous phasic contractions, both of which inhibited by magnesium. The study concluded that magnesium inhibited extracellular calcium entry, intracellular release, cystolic calcium oscillaions and phasic contractions of the myometrial smooth muscle.

Both magnesium and calcium acts as cofactors in the synthetic activity of variety of enzymes and in the secretory process. They bind to the fatal membrane and diffuse through the membrane which play a role in the synthesis or action of prostaglandins and generation of NO which are believed to regulate the myometrial activity. Nitric oxide is generated by nitric oxide synthase (NOS) from argenine. It has a relaxant effect on the myometrium and its relaxation is specially blocked by inhibitors of NOS¹¹⁵.

The presence of NOS has been demonstrated in myometrium, placenta and fetal membrane⁸⁴.

The activity of the NOS is dependent on calcium¹¹⁶ and this activity is inhibited by reduction in the concentration of magnesium¹¹⁷.

Adam et al showed that the diffusion of calcium and Mg across the fetal membranes was much lower in preterm than compared with the term¹¹⁸. The reduction in the availability of calcium in the myometrium and the placenta would result in down regulation of nitric oxide synthase activity and thereby reduction in the NO production. This mechanism along with an effect on intracellular calcium transport resulting from a reduced availability of magnesium would lead to increased myometrial activity in preterm labor.

Magnesium has a membrane stabilizing action which contributes in stabilization of highly ordered organization of macro-cellular structures DNA, RNA and ribosome. Magnesium also has a local anesthetic activity and depresses myoneural transmission which acts by reducing quantal release of acetylcholine and by antagonizing its depolarizing effect at the motor end plate and by reducing the excitability of muscle cell membrane¹⁰⁹.

Shaheena Kamel et al¹⁰⁹ and Deo P et al¹¹⁹ have found out that the serum magnesium level was significantly lower in preterm labour cases (1.47mg% +/- 0.22 SD) as compared to the normal pregnant women (1.9 mg% +/- 0.3 SD).

They have also demonstrated that lower the socioeconomic status, lower is the magnesium level. But they could not relate any significant findings with the age and parity on magnesium levels. Hypomagnesemia seems to be associated with vegetarian diet also.

In another study by Agrawal U et al there was hypomagnesemia in habitual abortion and premature labour were significantly lower in third trimester of pregnancy¹²⁰. They have concluded that serum magnesium level should be within the range of 1.5 to 3.5 mg%.

Kurzel RB found that women with preterm labor have significantly depressed magnesium level which was independent to the etiology of preterm labour. He has defines hypomagnesaemia of less than 1.4 mg% as a marker for preterm labour¹⁰⁷.

Smorlarczyk. R, et al, in their study have compared the calcium, phosphorous and magnesium of women with threatened preterm delivery between 29 weeks to 36 weeks of gestation with those of uncomplicated pregnancy of the same duration. There was hypomagnesaemia in patients with threatened preterm delivery and also low levels of calcium and phosphorous. They have explained that it might be due to premature uterine contractility, but did not predict premature labor after 36 weeks of gestation¹²⁰.

Caroline A Crowthe, et al, (2014) have searched the Cochrane Pregnancy and Childbirth Group's Trials Register (last searched 31 January 2014)¹²¹. They conducted a Randomised controlled trials of magnesium sulphate as the only tocolytic, administered by any route, compared with either placebo, no treatment or alternative tocolytic therapy (not magnesium sulphate) to women considered to be in preterm labour. Magnesium sulphate is ineffective at delaying birth or preventing preterm birth, has no apparent advantages for a range of neonatal and maternal outcomes as a tocolytic agent and its use for this indication may be associated with an increased risk of total fetal, neonatal or infant mortality.

Helen C McNamara, et al (2015) searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 September 2015) and reference lists of retrieved studies¹²². Randomised trials was done, comparing different magnesium sulphate treatment regimens when used as single agent tocolytic therapy during pregnancy in women in

preterm labour. There is some evidence from a single study suggesting a reduction in the length of stay in the neonatal intensive care unit and a reduced risk of respiratory distress syndrome where a high-dose regimen of magnesium sulphate has been used compared with a low-dose regimen. However, given that evidence has been drawn from a single study (with a small sample size), these data should be interpreted with caution. Magnesium sulphate has been shown to be of benefit in a wide range of obstetric settings, although it has not been recommended for tocolysis. In clinical settings where health benefits are established, further trials are needed to address the lack of evidence regarding the optimal dose (loading dose and maintenance dose), duration of therapy, timing of therapy and role for repeat dosing in terms of efficacy and safety for mothers and their children. Ongoing examination of different regimens with respect to important health outcomes is required.

Shatha A et al, (2016), one hundred patients who admitted into the labour room of the hospital due to preterm labour (28 to 36+6 weeks of gestation)¹²³ whose etiology could not be explained by etiological factors were enrolled in this prospective case-control study during the period from June 2013 to June 2014. And another 80 women of comparable gestational age who were referred to the consultation clinic of their hospital for achieving prenatal care or for causes other than preterm labour, provided only those whose birth occurred after 37th week considered as a control group. Serum magnesium level was measured in both groups. In their study they have concluded that serum magnesium level can be used as a predicting tool for idiopathic preterm labour.

Jenabi et al, (2017) conducted an observational study was conducted at the Social Security Hospital in Hamadan City, the west of Iran, from October 2014 to January

2015¹²⁴. The case group included 32 preterm labour women (28 to less than 37 weeks pregnant women) and the control group included 32 term pregnant women. The maternal serum magnesium level, the duration of the first and second stage of labor were measured in both the groups.

They concluded that low level of maternal serum magnesium is associated with poor pregnancy outcomes, including preterm labor and low birth weight.

DOSAGE AND ADMINISTRATION:

HIGH DOSE: loading dose of 6gms intravenously over 15-30 mins followed by IV infusion at the rate of 2-6 gms/hr for maintenance with success rate of 88.7%.

LOW DOSE: loading dose of 4gms intravenously over 15-30 mins followed by IV infusion at the rate of 2gms/hr for maintenance therapy with success rate of 70.7%.

Drug is then titrated to levels of 5-8 mg/dl or until adequate tocolysis is achieved. Magnesium levels should be checked every 4-6 hrs.

Monitor vitals, intake output chart, deep tendon reflexes, respiratory rate every 2 hours to evaluate the evidence of drug toxicity.

Decreased or absent DTR represents an initial sign of toxicity (>10 mg/dl), respiratory depression (>15mg/dl) and myocardial depression at very high doses.

ANTIDOTE: 1gm of calcium gluconate intravenously.

CONTRAINDICATIONS;

ABSOLUTE: Myasthenia gravis.

RELATIVE:

- 1) Cardiac disease

2) Renal impairment

3) Concomitant use of calcium channel blockers.

106

SIDE EFFECTS:

SHORT TERM	LONG TERM	TOXICITY
MATERNAL Lethargy, nausea, vomiting, constipation, dry mouth, hypocalcemia,	Osteoporosis, tetany, renal stones, paralytic ileus, pulmonary edema, hypothermia, rhabdomyolysis.	absent DTR, respiratory depression, cardiac arrest, death.
FETAL Decreased fetal movements, absent fetal breathing, decreased short term variability of heart rate, altered uterine blood flow, blunted fetal response.	Decalcification of Bone	
NEONATAL Hypomagnesemia, hypocalcemia, lethargy, depressed APGAR, hypotonia, decalcification of bone.	HIGH DOSES Neonatal death	LOW DOSES Neuro protective (decreased incidence of cerebral palsy and IVH)

Magnesium sulfate as neuroprotection for preterm neonates:

Despite significant improvements in survival for infants born preterm, the rate of major neurodevelopmental impairment in survivors has not diminished. As a result, strategies designed to reduce adverse neurological outcomes have been a major perinatal research focus. Antenatal magnesium sulfate (MgSO_4) is one such strategy. Following the first report of an association between perinatal administration of MgSO_4 and a reduction in the risk of peri/intraventricular hemorrhage (P/IVH), its use as a neuro-protective therapy when given to women at risk of preterm birth has become established practice. While MgSO_4 has been shown to decrease the risk of P/IVH, cerebral palsy and the rate of substantial gross motor dysfunction, the mechanisms underlying these effects remain poorly understood.

Pamela Borja-Del-Rosario et al (2014)¹²⁵, conducted a retrospective study on 289 mothers who received antenatal magnesium for neuroprotection as a loading dose of 4–6 g infused over 30 min, followed by a maintenance infusion of 1–2 g/h. Total magnesium dose infused to the mother and maternal serum magnesium concentrations were correlated with neonatal serum magnesium concentrations. They have concluded that the total dose of magnesium infused to the mother correlates with neonatal serum magnesium concentrations. To keep neonatal serum magnesium concentrations within a range that is effective for neuroprotection and safe for the neonates, the total dose received by the mother needs to be monitored and limited.

Michael J. Stark et al (2015)¹²⁶ in their study of CBF and tissue oxygenation index were measured, and oxygen delivery, consumption, and cFTOE calculated within 24 h of birth and at 48 and 72 h of life in 36 infants ≤ 30 wk gestation exposed to MgSO_4 and 29 unexposed infants. The total internal carotid blood flow and cerebral oxygen delivery did not differ between the groups at the three study time-points. Cerebral oxygen consumption and cFTOE were lower in infants exposed to antenatal MgSO_4 ($P = 0.012$) compared to unexposed infants within 24 h of delivery. This difference was not evident by 48 h of age. Fewer infants in the MgSO_4 group developed P/IVH by 72 h of age ($P = 0.03$). They have concluded that infants exposed to MgSO_4 had similar systemic and cerebral hemodynamics but lower cFTOE compared to nonexposed. These findings suggest reduced cerebral metabolism maybe a component of the neuro-protective actions of antenatal MgSO_4 .

However, Betsy Ostrander, et al (2016)¹²⁷ performed a retrospective cohort analysis in infants born <37 weeks gestation over a 10-year period. Prenatal, perinatal, and postnatal clinical and demographic information was collected. Crude and adjusted odds ratios were estimated under generalized linear models with generalized estimating equations to examine the association of the neonatal serum magnesium level between 24 and 48 hours following birth with the risk of epilepsy and/or motor impairment. The final cohort included 5,461 infants born <37 weeks gestation from 2002–2011. This study shows that the neonatal magnesium level between 24 and 48 hours of life in premature infants is not significantly associated

with the risk for developing epilepsy or motor impairment.

Another study by Sajjad Ur Rahman et al (2017)¹²⁸, a multicenter double-blind randomized controlled trial in which the term and near-term newborn infants (≥ 35 weeks) with a clinical diagnosis of moderate or severe HIE were randomized to either Arm A (therapeutic hypothermia plus MgSO_4) or Arm B (therapeutic hypothermia plus placebo) using a net-based randomization system. Both groups received, within 6 h of birth, standard hypothermia therapy (72 h of cooling to 33.5°C followed by slow rewarming over a period of 8 h) plus either MgSO_4 (250 mg/kg/dose $\times 3$ doses) or placebo (normal saline). The groups were compared for short-term predischARGE adverse outcomes. They have concluded that the combined use of therapeutic hypothermia and MgSO_4 appears to be safe particularly with respect to maintaining normal blood pressure and coagulopathy. Long-term survival and neurodevelopmental outcomes remain to be evaluated.

METHODS AND MATERIALS

SOURCE OF DATA: All patients who present to Dept. of Obstetrics and Gynaecology R.L.Jalappa Hospital and Research Centre Tamaka, Kolar with preterm labour and uncomplicated pregnancies of the same gestational age who meet the inclusion/exclusion criteria were included in the study. The duration of the study was from October 2015 to October 2017. A minimum of 100 subjects were proposed to be included in this study. Serum magnesium levels was estimated by Fusion 5.1 FS Micro slide method.

INCLUSION CRITERIA:

All pregnant women of any age group attending as out patient or in patient to R L JALAPPA Hospital, Tamaka, kolar with 28 weeks to 36 weeks 6 days of gestational age in preterm labour or not in labour. And the patient was followed up till delivery.

EXCLUSION CRITERIA:

1. Previous history of recurrent abortions or preterm delivery.
2. Patients with recurrent urinary tract infections.
3. Patients with preeclampsia, polyhydramnios, antepartum haemorrhage, fetal congenital malformations, intrauterine death.
4. Patient with preterm premature rupture of membranes.
- 6 . Patients with cervical incompetence or any uterine malformations.
7. Patients with multiple gestation.

Prospective case control study.

Study group: Consisted of 50 pregnant women with preterm onset of labour (between 28 weeks to 36 weeks 6 days of gestation) and had preterm deliveries.

Control group: Consisted of 50 pregnant women with comparable gestational age (between 28 weeks to 36 weeks 6 days of gestation) attending the OPD for routine ANC and they were followed up till delivery

Method of collection of samples.

Patients were selected using the above criteria. After institutional clearance and informed consent blood samples was being collected as follows:

Group 1(study group): Blood samples was collected at the time of admission to labor room.

Group 2(control group): Blood samples was collected in out patients department. They were followed up till delivery.

Methods: 2ml of venous blood was collected in a plain tube from 28 weeks onwards of gestation and patients are followed up till delivery.

METHODOLOGY:

Demographic details of women like socioeconomic status, gravidity, gestational age as well as obstetric factors like history pain abdomen, frequency of uterine contraction, past obstetric history and any medical or obstetric complications were noted.

Gestational age was based on LMP, if LMP and first trimester scan was corresponding. If not earlier ultrasound measurement was used to determine the gestational age. Those who did not have a dating scan where gestational age could not be determined accurately were excluded.

Women were classified to different socioeconomic status which we used BG Prasad classification (2014) based on the husband occupation.

The frequency of uterine contraction was assessed by abdominal examination. Per speculum examination was done to look for dilatation. Per vaginal examination was done to feel the effacement of cervix and diagnosis of preterm labor was made.

Serum venous sample were collected for the estimation of magnesium before any parenteral therapy as describe above. Serum magnesium was estimated by Fusion 5.1 FS magnesium Micro slide method.

The neonatal outcomes were assessed by noting birth weight, APGAR scores at 1 minute and 5 minute, any neonatal morbidity and NICU admission.

SAMPLE SIZE CALCULATION

Sample Size For Comparing Two Means

Input Data

Confidence Interval (2-sided)	95%	
Power	90%	
Ratio of sample size (Group 2/Group 1)	1	
	Group 1	Group 2
	Difference*	
Mean	0.23	
Standard deviation	0.3	0.4
Variance	0.09	0.16

Sample size of Group 1	50
Sample size of Group 2	50
Total sample size	100

STATISTICAL ANALYSIS

The collected information was coded and entered to an excel data sheet. The quantitative measured are presented by mean and standard deviation and the qualitative measured are presented by proportions and confidence interval.


The significance of the difference in the quantitative measure stands by using student 't' test. The difference is qualitative measure between the group by using chi square test. p-value less than or equal to 0.05 was considered as statistically significance

Analysis of serum magnesium levels:

After collecting serum samples was separated by centrifugation and used for analysis.

Serum magnesium is measured by Fusion 5.1 FS magnesium Micro slide method.

Magnesium reacts with formazam dye derivatives in the reagent layer; the high magnesium affinity of the dye dissociated magnesium from binding proteins. The resulting magnesium dye complex cause a shift in the dye absorption maximum. The amount of dye complex form is proportional to the magnesium concentration present in the samples and measured by reflection density.



(this complex is measured)

REFERENCE VALUE:

Serum magnesium 1.6 to 2.6 mEq / l. ⁴

RESULTS

This was a prospective study where serum magnesium levels were estimated in a group of 50 women who was presented with preterm labor and delivered preterm (study group) and compared with a group of 50 women who delivered at term (control group) to determine the possible role of magnesium in initiation of preterm labor.

The following are the results of the analysis:

1) The comparison of age in years in study and control group:


The mean age of the patients in the study group was 22.4 ± 3.084 while that in the control group was 22.4 ± 3.064 .

Majority of the patients in both the age groups were in the age group of 21 to 25 years.

Table.no.3. Comparison of age in years in Study and Control group.

Age in years	Study group NO. (N=50)	Study group in percentage(%)	Control group NO. (N=50)	Control group percentage (%)
18 to 20	17	34	18	36
21 to 25	23	46	22	44
26 to 30	20	20	10	20
TOTAL	50	100	50	100
Mean SD	22.4 ± 3.084		22.4 ± 3.064	

Figure. No. 5. Bar chart of Age distribution among study and control group.




2) The distribution of parity in study and control group:

Primigravida are more common in both study group and control group constituting 55% of Cases.

Table. No. 4. Distribution of parity in study and control group.

PARITY	Frequency	Percentage
Multigravida	45	45.00%
Primigravida	55	55.00%

Figure.6. Bar chart of PARITY distribution in study population (N=50) and control population (N=50).




3) The comparison of gestational age in study and control group:

In study group most cases is in between 34 weeks to 36 weeks 6days contributing of 80%

Table.no. 5. The comparison of gestational age in study and control group.

Gestational age	Group	
	Study (N=50)	Control (N=50)
28 weeks to 30 weeks	0 (0%)	7 (14%)
30 weeks 1 day to 32 weeks	0 (0%)	11 (22%)
32 weeks 1 day to 34 weeks	10 (20%)	18 (36%)
34 weeks 1 day to 36 weeks 6 days	40 (80%)	14 (28%)

Figure.no.7. Bar chart of Gestational age distribution in study population (N=50) and control population (N=50).




4) The comparison of Socioeconomic status in study and control group:

In the study group most of the cases falls in lower middle class of BG Prasad socioeconomic status constituting of 28%, however, in control group most of the cases falls in middle class (52%) followed by upper middle class (42%).

Table. No. 6. The comparison of Socioeconomic status in study and control group.

Socioeconomic status	Group	
	Study (N=50)	Control (N=50)
Upper class	0 (0%)	3 (6%)
upper middle class	13 (26%)	21 (42%)
middle class	13 (26%)	26 (52%)
lower middle class	14 (28%)	0 (0%)
lower class	10 (20%)	0 (0%)

Figure.no.8. Bar chart of Socioeconomic status distribution in study population (N=50) and control population (N=50).



5) Distribution of mode of delivery in study and control group:

Most (62%) of the women had preterm vaginal delivery in study group, and in control group most (66%) of the women delivered by full term vaginal delivery.

Table. No. 7. Distribution of mode of delivery in study and control group:

MOD	Group	
	Study (N=50)	Control (N=50)
asst breech	1 (2%)	0 (0%)
ftvd	0 (0%)	33 (66%)
lscs	14 (28%)	12 (24%)
out force	0 (0%)	4 (8%)
out forcep	4 (8%)	0 (0%)
ptvd	31 (62%)	0 (0%)
vacuum	0 (0%)	1 (2%)


6) The comparison of sex of baby in study and control group:

Majority of the baby in both study (58%) and control (52%) were male baby.

Table.no. 8. The comparison of sex of baby in study and control group:

Sex of baby	Study group NO. (N=50)	Study group in percentage(%)	Control group NO. (N=50)	Control group percentage (%)
Male	29	58	26	52
Female	21	42	24	48

Figure.no.9. Bar chart of sex of baby in study population (N=50)




7) The comparison of birth weight of baby (Kg) in study and control group:

The mean birth weight of the baby in study population is 2.1 kg with SD of 0.34 and in control group is 3.09 kg with SD of 3.09. The p-value being <0.001, which is highly statistically significant.

Table. No. 9. The comparison of birth weight of baby (Kg) in study and control group.

Group	WEIGHT Mean± STD	Mean difference	95% CI		P value
			Lower	Upper	
Study (N=50)	2.1 ± 0.34	-0.98	-1.11	-0.86	<0.001
Control (N=50)	3.09 ± 0.29				

Figure.no. 10. Bar chart of weight of baby (Kg) in study population (N=50) and control population (N=50).




8)The comparison of APGAR SCORE in study (N=50) and control (N=50) group:

The mean APGAR score of the baby in study population is 6.58 with SD of 0.54 at 1 min and 8.56 with SD of 0.54 at 5 min, and in control group is 7 at 1 min and 9 at 8 min. The p-value being <0.001, which is highly statistically significant.

Table.no. 10.The comparison of APGAR SCORE in study (N=50) and control (N=50) group:

Parameter	Mean \pm SD		P value
	Study (N=50)	control (N=50)	
AGPAR 1 min	6.58 \pm 0.54	7 \pm 0	<0.001
APGAR 5 min	8.56 \pm 0.54	9 \pm 0	<0.001

Figure.no. 11. Bar chart of AGPAR between study group (N=50) and control group (N=50).




9) Comparison of neonatal outcome in study (N=50) and control (N=50) group.

In study group 38 % of the baby was admitted to NICU, however in control group none of the baby had required NICU admission.

Table.no. 11. Comparison of neonatal outcome in study (N=50) and control (N=50) group.

NICU	Group	
	Study (N=50)	Control (N=50)
yes	19 (38%)	50 (100%)
No	31 (62%)	0 (0%)

Figure.no. 12. Bar chart of NEONATAL OUTCOME between study group (N=50) and control group (N=50).



10) Comparison of mean Serum Mg mEq/L across study groups (N=50) and control group (N=50).

The mean serum magnesium level (mEq/L) in study population is 1.39 mEq/L with SD of 0.2 and in control group is 2.08 mEq/L with SD of 0.2 . The p-value being <0.001, which is highly statistically significant.

Table.no. 12. Comparison of mean Serum Mg mEq/L across study groups (N=50) and control group (N=50).

Group	Mg (mEq/L) Mean± STD	Mean difference	95% CI		P value
			Lower	Upper	
Study (N=50)	1.39 ± 0.2	-0.69	-0.77	-0.61	<0.001
Control (N=50)	2.08 ± 0.2				

Figure.no. 13. Bar chart distribution of Serum Mg in study group (N=50) and control group.





Figure.no. 14. Box and whisker plot of distribution of Mg level in mEq/L in study group (N=50) and control group(N=50)



11) Distribution of mean magnesium(mEq/L) in different Socioeconomic status in study and control group.

The low level of mean serum magnesium is observed in lower middle class which is 1.29 with SD of 0.14 and in lower class is 1.28 with SD of 0.1. The p-value being 0.003 and 0.004 respectively which is statistically significant.

Table.no. 13. Distribution of mean magnesium (mEq/L) in different Socioeconomic status in study and control group.

SOCIOECONOMIC STATUS	Mean \pm Std. Dev	Mean difference	95% Confidence Interval for Mean		P value
			Lower Bound	Upper Bound	
Upper class	1.9 \pm 0.1				
upper middle class	1.9 \pm 0.32	0.00	-0.38	0.38	1.000
middle class	1.85 \pm 0.39	0.05	-0.32	0.43	0.787
lower middle class	1.29 \pm 0.14	.6071	0.21	1.01	0.003
lower class	1.28 \pm 0.1	.6200	0.21	1.03	0.004

Figure.no. 15 : Bar chart of Socioeconomic Status distribution in study and control group.




Figure.no. 16. Box and whisker plot of Serum Mg level (mEq/L) in different Socioeconomic Status between study and control group.





Figure.no.17: Correlation between Gestational age at time of testing and serum Mg (mEq/L) in the study group (N=50) and control Group (N=50).



The value of serum magnesium levels decrease with the increase in gestational age in both study and control group.

DISCUSSION

The main focus in the current study to compare the serum magnesium level in preterm birth and in those who had a term delivery, many records findings have augmented measuring magnesium level as a predictor for preterm birth. The exact cause of hypomagnesaemia in patient of preterm birth is unknown but individualized and socioeconomic factors have been considered.

Based on the results of a case-control study conducted by Bhat et al¹ in 2012, serum magnesium level in women with preterm labor was significantly lower than women with term labor (1.343 ± 0.09 mg/dl versus 1.875 ± 0.013 mg/dl, respectively). In addition, Hantoushzadeh et al⁵ reported that serum magnesium level in preterm pregnant women was lower than term pregnant women (1.7 ± 0.38 versus 2 ± 0.184).

STUDIES	Preterm labour	Normal pregnancy
Present study	1.39 ± 0.2 mEq/L	2.08 ± 0.2 mEq/ L
Bhat et al ¹	1.343 ± 0.09 mg/dl	1.875 ± 0.013 mg/dl
Hantoushzadeh et al ⁵	1.7 ± 0.38 mg/dl	2 ± 0.184 mg/dl
Ensiyeh Jenabi et al ¹³⁰	1.95 ± 0.16 mg/dl	2.12 ± 0.27 mg/dl
Kamal et al ¹⁰⁹	1.47 ± 0.22 mg/dl	1.75 ± 0.21 mg/dl

Kurzel¹⁰⁷ investigated the effect of serum magnesium levels in pregnancy on preterm labor and indicated that hypomagnesaemia (magnesium equal to or less than 1.4 mg/dl) can be considered as a marker for true preterm labor. A proposed hypothesis suggests that magnesium has an immediate effect on placenta vascular flow and its depletion can have

an adverse effect on the placenta vascular dilation leading to placenta insufficiency.

Jenabi et al, (2017)¹²⁹ conducted an observational study concluded that low level of maternal serum magnesium is associated with poor pregnancy outcomes, including preterm labor and low birth weight. In addition, there was a direct correlation between maternal serum magnesium level, gestational age and neonatal weight.

Durlach J,et al ¹³⁰. concluded that exact cause of hypomagnesemia in patients of preterm labour is not known but nutritional and socio-economic factors have been suggested for it.

Neuromuscular hyperexcitability is an initial problem cited in individuals who have or are developing magnesium deficiency. Neuromuscular hyperexcitability in turn leads to uterine hyperactivity resulting in premature onset of labour

In present study a number of preterm labour cases belong to lower middle class and lowerclass of BG Prasad socioeconomic status and it is similar as Sharma A et al ¹³¹ findings.

On the contrary Khani et al¹³² demonstrated non-significant increase in preterm labour among low socioeconomic class women may be due to the smaller sample size in his study when he took only 40 pregnant women.

This increase in preterm labour in low socioeconomic class may be attributed to poor prenatal care, stressful life style and nutritional deficiency of trace elements includingmagnesium.

Kamal S et al ¹⁰⁹, (*Indian J Pathol Microbiol* 2003) also observed in their study that low Level of serum magnesium is detected in lower socioeconomic status than compared to higher socioeconomic status.

Regarding magnesium level at different gestational age, we observed that there was a decrease in serum magnesium with progression of pregnancy in both groups, and the same is observed in Bhat S, et al ¹.

Gestational age	Serum Magnesium in mg/dl (Group 1)	Serum Magnesium in mg/dl (Group 2)	Statistical analysis (p-value)	Remarks
(28-30) weeks	1.37+- 0.055	1.97+- 0.073	<0.001	HS
(31-33) weeks	1.35+- 0.63	1.89 +- 0.84	< 0.001	HS
(34- 36) weeks	1.31+- 0.060	1.77 +- 0.111	< 0.001	HS

*HS – highly significant.

Shatha A, et al¹³³. also concluded that as the gestational age of the pregnancy increase the serum magnesium level is observed to be decreased ,which may due to increased demand with the advance of pregnancy.

Watson et al,¹³⁴ performed a prospective cohort study on 504 pregnant women in New Zealand in 2010 and investigated the association between infant birth weight and maternal diet and supplement intake. They reported a positive correlation between magnesium intake during pregnancy and neonatal birth weight.

In the present study the mean birth weight of the baby in study population is 2.1 kg with SD of 0.34 and in control group is 3.09 kg with SD of 3.09. The p-value being <0.001 , which is highly statistically significant. Elezabeth Kh et al¹³⁵, in their study showed that serum magnesium to be lowest in preterm low birth weight newborns, then term low birth weight (including IUGR) infants, and then term normal control.

On the other hand, Pourarian et al¹³⁶ conducted a case-control study on 180 pregnant women in 2014 and reported no significant association between maternal magnesium level and infant birth weight and gestational age.

Moreover, the mean APGAR score of the baby in study population is 6.58 with SD of 0.54 at 1 min and 8.56 with SD of 0.54 at 5 min, and in control group is 7 at 1 min and 9 at 8 min.

The p-value being <0.001 , which is n also highly statistically significant. Also, in study group 38 % of the baby was admitted to NICU, however in control group none of the baby had required NICU admission.

A study conducted by Cunze et al¹¹³. on magnesium and calcium concentration in the pregnant and non-pregnant myometrium concluded that low magnesium concentration in the pregnant human myometrium could be a cause of preterm labour.

Further studies have demonstrated that prophylactic oral magnesium supplementation to patient at risk of preterm labour was successful in lowering the

preterm delivery rate and intake should be sufficient to maintain serum magnesium level at the range of 2.0 - 3.5 mg/dl ¹³⁷.

However, larger studies need to be initiated to conclusively prove the role of hypomagnesaemia in the initiation of preterm labour. If proved so, estimation of magnesium levels in early pregnancy could be simple and easy to perform and cost effective test to detect women at risk for preterm delivery. Availability of a marker for preterm labour would initiate more research in the direction of interventions for prevention and would ultimately give the way for primary prevention, thereby reducing the morbidity and mortality associated.

Magnesium supplementation itself could be simple and inexpensive intervention towards prevention of preterm labour.

SUMMARY

The magnitude of preterm labour and subsequent neonatal morbidity and mortality provoked our study to investigate the possible role of serum magnesium deficiency in triggering the onset of preterm labour.

We compared the serum magnesium levels of 50 women who delivered at 28 weeks to 36 weeks and 6 days of gestation with serum magnesium levels of women between weeks to 36 weeks and 6 days but delivered after 37 completed weeks of gestation.

1. The mean serum magnesium levels in the study group was 1.39 ± 0.2 mEq/L which was significantly lower than the control group 2.08 ± 0.2 mEq/L.
2. Serum magnesium levels were also lower in lower socioeconomic status in both study and control group.
3. The birth weight of the baby in study group is 2.1 ± 0.34 kg and in control group is 3.09 ± 0.29 kg, which is statistically significant.
4. The mean APGAR score of the baby in study population is 6.58 with SD of 0.54 at 1 min and 8.56 with SD of 0.54 at 5 min, and in control group is 7 at 1 min and 9 at 8 min. The p-value being <0.001 , which is highly statistically significant.
5. In study group 38 % of the baby was admitted to NICU, however in control group none of the baby had required NICU admission.
6. The value of serum magnesium levels decrease with the increase in gestational age in both study and control group

CONCLUSION

Serum magnesium levels in our study were significantly lower in those who delivered preterm when compared with those who delivered at term, this suggest a possible role of hypomagnesemia in initiation of preterm labour.

Pregnant women should be counseled to include good sources of magnesium in their diets, such as nuts, seeds, green leafy vegetables and fish.

Identifying deficiency is the safest and most effective way to determine supplement requirements. In the absence of this, a low dose magnesium could be safely recommended to prevent women in general, eg. 100- 200 mg/day.

Larger studies are required to conclusively prove the role of hypomagnesemia in preterm labour.

REFERENCES:

1. Bhat S , Waheed A, Chisti T, Habib Huma. Hypomagnesemia as a marker for preterm labour and its association with socio economic status. JIB. 2012;1: 24 -30.
2. Bhat S, Waheed A. Serum magnesium levels in preterm labour. sljog. 2012;34: 37-44.
3. Enaruna No, Ande ABA, OKpere EE. Clinical significance of low serum magnesium in pregnant women attending the University of Benin Teaching Hospital. NJCP 2013;16: 448-453.
4. Okunade Kehinde S, Oluwole Ayodeji A, Adegbesan- Omilabu Mayumunah A.A study on the Association between Low Maternal serum magnesium level and preterm labour. Hindawi. 2014;71:1-6
5. Hantoushzadeh S, Jafarabadi M, Khazardoust S. Serum magnesium levels, muscle cramps and preterm labour. Int J Gynae Obst. 2007;98: 153-154.
6. Ar Shahid , Au Hosna, Hz Tahmina. Hypomagnesaemia in Pregnancy : a predictor of preterm labour. J Dhaka Med coll. 2010; 19 : 51- 57.
7. Baloch Ghulam Hussain ,Shaikh Khalida, Jaffery Mukhtiar Hussain .Serum Magnesium Level During Pregnancy. WASJ. 2012;17:1005- 1008.
8. Roy Vijay, GS Prasad. Tocolysis with Ritodrine. A comparative study in preterm labour. Pak J Med Sci. 2006; 22:271-273.
8. Roy Vijay, GS Prasad. Tocolysis with Ritodrine a comparative study in preterm labour. Pak J Med Sci. 2006; 22:271-273.

-
9. Esplin MS, Merrell K, Goldenberg R, et al; the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units. Proteomic identification of serum peptides predicting subsequent spontaneous preterm birth. *Am J Obstet Gynecol* 2011;204:391.e1-8.
 10. O'Brien J.M., Lewis D.F: Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies. *J Reprod Med* 2009;54. 73-87.
 11. Potdar N., Singh R., Mistry V., et al: First-trimester increase in oxidative stress and risk of small-for-gestational-age fetus. *BJOG* 2009;116: 637-642.
 12. Polivka B J, Nickel J T, Wilkins , III , III J R : Urinary tract infection during pregnancy: a risk factor for cerebral palsy?. *J Obstet Gynecol Neonatal Nurs* 1997;26:405-413.
 13. O'Shea T.M.: Cerebral palsy in very preterm infants: new epidemiological insights. *Ment Retar Dev Disabil Res Rev* 2002;8:135-145.
 14. Spinillo A., Capuzzo E., Stronati M., Ometto A., De S.A., Acciano S. Obstetric risk factors for periventricular leukomalacia among preterm infants. *Br J Obstet Gynaecol* 1998;105:865-871.
 15. Arias, Deftary, Bhide. Preterm parturition syndrome. *Practical Guide to High Risk Pregnancy and Delivery: A South Asian Perspective*, 3rd Edition 2008: 193-204.
 16. Spong CY: Defining "term" pregnancy. Recommendations from the Defining "Term" Pregnancy Workgroup. *JAMA* 309(23):2445, 2013.

-
- 17.ACOG committee opinion no. 560: Medically indicated late-preterm and early-preterm deliveries. *Obstet Gynecol.* 2013; 121 (4): 908-910.
 - 18.Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New interuterine growth curves based on United States data. *Pediatrics.* 2010; 125:e214. [PubMed: 20100760]
 19. World Health Organization. March of Dimes sixth annual premature report. November 2013.
 20. World Health Organisation. Preterm birth. November 2016.
 - 21.Registrar General of India. Sample registration system (SRS) statistical report 2013. New Delhi: 2013. 22. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. *Lancet* 2015; 385(9966): 430–440.
 23. Baqui AH, Darmstadt GL, Williams EK, Kumar V, Kiran TU, Panwar D et al. Rates, timing and causes of neonatal deaths in rural India: implications for neonatal health programmes. *Bull World Health Organ* 2006; 84: 706–713.
 24. ICMR Young Infant Study Group. Age profile of neonatal deaths. *Indian Pediatr* 2008; 45: 991–994.
 25. Bang AT, Paul VK, Reddy HM, Baitule SB. Why do neonates die in rural Gadchiroli, India? (Part I): primary causes of death assigned by neonatologist based on prospectively observed records. *J Perinatol* 2005; 25(Suppl 1): S29–S34.

-
26. Mathews TJ, MacDorman MF: Infant mortality statistics from the 2009 period linked birth/infant death data set. *Natl Vital Stat Rep* 61(8):1, 2013.
 27. Hamilton S, Oomomian Y, Stephen G, et al: Macrophages infiltrate the human and rat decidua during term and preterm labor: evidence that decidual inflammation precedes labor. *Biol Reprod* 86(2):39, 2012
 28. World RA, Li XH, et al. Dynamics of cervical remodeling during pregnancy and parturition: mechanism and current concepts. *Semin Reprod Med.* 2007;25:69.
 29. Timmons B, Akins M, et al. Cervical remodeling during pregnancy and parturition. *Trends Endocrinol Metab.* 2010;21:353.
 30. S.Arul Kumaran, S S Rathnam, K Bhaskar Rao. The management of labor. 1st edition , Preterm labor 1996:258-282.
 31. Woodcock NA, Taylor CW, Ornton S: Effect of an oxytocin receptor antagonist and rho kinase inhibitor on the $[Ca^{++}]_i$ sensitivity of human myometrium. *Am J Obstet Gynecol* 190:222, 2004.
 32. Parkington HC, Coleman HA: Excitability in uterine smooth muscle. *Front Horm Res* 27:179, 2001
 33. Brainard AM, Miller AJ, Martens JR, et al: Maxi-K channels localize to caveolae in human myometrium: a role for an actin-channel-caveolin complex in the regulation of myometrial smooth muscle K^+ current. *Am J Physiol Cell Physiol* 289:C49, 2005
 34. Chanrachakul B, Matharoo-Ball B, Turner A, et al: Immunolocalization and protein expression of the alpha subunit of the large-conductance calcium-activated

potassium channel in human myometrium. *Reproduction* 126:43, 2003.

35. Jones BS,A. Cervical cerclage. In:critchley HO, Bennett PR,Thornton S, eds. Preterm birth. RCOG Press;2004.
36. Norwitz ER RJ, Greene M. Cervical Cerclage- elective and emergent. ACOG update. 1999; 24: 1-11.
37. Slattery MM, Morrison JJ, Sachs L, Gebauer C, Samuels P. Cervical competence as a continuum: A study of ultrasomographic cervical lengh and obstetric performance. *Am J Obstel Gynecol.* 1995; 172(4):1097-1106.
38. Iams JD, Johnson FF, Sonck J, Sachs L, Gebauer C, Samuels P. Cervical competence as a continuum: A study of ultrasonographic cervical length and obstetrics performance. *Am J Obstel Gynecol.* 1995; 172 (4): 1097-1106.
39. Guzman ER, Mellon R, Vintzileos AM, Ananth CV, Walters C, Gipson K. Relationship between endocervical canal length between 15-24 weeks gestation and obstetrics history. *J Matern Fetal Med.*1998; 7 (6): 269-272.
- 40.Andrews WW, Copper R, Hauth JC, Goldenberg RL, Neely, Dubard M. Second-trimester cervical ultrasound: associations with increased with increased risk for recurrent early spontaneous delivery. *Obstel Gynecol.*2000;95(2):222-226.
41. Cook CM, Ellwood DA. The cervix as a predictor of preterm delivery in ‘at – risk’ womwn. *Ultrasound obstel gynecol.* 2000;15 (2): 109-133.
42. Berghella V DSF, Tolosa JE,Di Vito MM, et al. prediction of preterm delivery with transvaginal ultrasonography of the cervix in patients with high –risk pregnancies:

does cerclage prevent prematurity? Am J Obstet Gynecol. 1999; 181 (4): 809-815.

43. David F Colombo, Jay D Iams. Cervical length and preterm labor. Clinical Obstetrics and Gynecology 2000; vol 43:735-745.
44. Kaufman RH. Structural changes of the genital tract associated with in utero exposure to diethylstilbestrol. Obstet gynecol annu. 1982;11: 187-202.
45. Vyas NA, Vink JS, Ghidini A, et al. Risk factors for cervical insufficiency after term delivery. Am J obstet GYnecol. 2006; 195 (3): 787-791.
46. Kyrgiou M KG, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systemic review and meta-analysis. Lancet. 2006;367 (9509): 489-98.
47. Berghella V TJ, Kuhlman K, Weiner S, Bolognese RJ, Wapner RJ. Cervical ultrasonography compared with manual examination as a predictor of preterm delivery. Am J Obstet Gynecol. 1997;177(4):723-730.
48. Berghella V. The cervix, In: Preterm Birth- Prevention and management, 1st edn; 2010, pp.50-6, WQ 330 P91965.
49. Goldenberg RL II, Miodovnik M, Van Dorsten JP, et al. The preterm prediction study: risk factors in twin gestations. National institute of Child and Human Development Maternal- Fetal Medicine Units Network. Am J Obstet Gynecol. 1996;175(4 Pt 1): 1047-1053.

-
50. Geoffrey Chamberlain, Philip Steer. Turnbolls Obstetrics 3rd edition 2001:494-497.
51. Creasy resnik. Maternal Fetal medicine 4th edition 1999:499-502.
52. Visintine J, Berghella V, Henning D, Baxter J. Cervical length for prediction of preterm birth in women with multiple prior induced abortions. Ultrasound Obstet Gynecol. 2008; 31 (2): 198-200.
53. RCOG. The care of women requesting induced abortion. In National Evidence Based Clinical Guidelines RCOG;2001.
54. Romero R, Gonzalez R, Sepulveda W, et al. Infection and labor. V11. Microbial invasion of the amniotic cavity in patients with suspected cervical incompetence prevalence and clinical significance. Am j obstet Gynecol. 1992;167(pt 1): 1086-1091.
55. Mays JK, Figueroa R, Shah J, Khakoo H, Kaminsky S. Tejani N. Amniocentesis for selection before rescue cerclage. Obstet Gynecol. 2000;95 (5): 652-655.
56. Boggess KA, Madianos PN, Preisser JS, Moishw KJ, Jr., Offenbacher S. Chronic maternal and fetal Porphyromonas gingivalis exposure during pregnancy in rabbits. Am J Obstet Gynecol. 2005;192 (2): 554-557.
57. Stattey MM, Morrison JJ, Preterm delivery. Lancet. 2002; 360 (9344): 1489-1497.
58. Donders GG, Van Calster C, Bellen G, et al. Association between abnormal vaginal flora and cervical length as risk factors for preterm birth. Ultrasound Obstet Gynecol. 2010.
-

-
59. Donders GG, Van Calster K, Bellen G, et al. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. *BJOG*.2009;116(10):1315-1324.
60. Romero R, Emamian M, Quintero R. The value and limitation of the gram stain examination in the diagnosis of Intraamniotic infection. *Am j Obstet Gynecol* 1988;159:114.
61. Romero R, Kadar N, Hobbins JC. Infection and Labor. The detection of endotoxin in amniotic fluid. *Am J Obstet Gynecol* 1987;157:815.
62. Gravett MG, Eschen Bach, Speigl Brown CA. Rapid diagnosis of amniotic fluid infection by gas liquid chromatography. *N Eng J Med* 1982;306:727.
63. Hillier SL, Martius K, Krohn M, A case controlled study of chorioamniotic infection and histologic chorioamnionitis in Prematurity. *N Engl Med* 1998;319:972-978.
64. Bloom SL, Yost NP, MC Intire. Recurrence of preterm birth in singleton and twin pregnancies. *Obstet Gynecol* 2001b;98:379.
65. Mercer BM. Preterm premature rupture of the membranes. *Obstet Gynecol*.2003;101(1):178-193.
66. Douvas SG, Brewer MJ, McKay ML, Rhodes PG, Kahlstrof JH, Morrison JC. Treatment of premature rupture of the membranes. *J Reprod Med*.1984;29 (10):741-744.

-
67. Merenstein GB, Weisman LE. Premature rupture of the membranes: neonatal consequences. *Semin Perinatal*. 1996;20(5): 375-380.
68. Sebire NJ, Carroll SG, Newbold M, Nicolaides KH. Preterm prelabour amniorrhexis :relation to histological chorioamnionitis. *J Matern Fetal Med*. 1996;5(5):227-231.
69. Broekhuizen FF, Gilman M, Hamilton PR. Amniocentesis for gram stain and culture in preterm premature rupture of the membranes. *Obstet Gynecol*. 1985;66(3):316-321.
70. Cotton DB, Hill LM, Strassner HT, Platt LD, Ledger WJ. Use of amniocentesis in preterm gestation with ruptured membranes. *Obstet Gynecol*. 1984;63(1):38-43.
71. Anum EA, Hill LD, Pandya A, Strauss JF, 3rd. Connective tissue and related disorders and preterm birth: clues to genes contributing to prematurity. *Placenta*. 2009;30(3):207-215.
72. Berghella V, Pereira L, Gariepy A, Simonazzi G. Prior cone biopsy: Prediction of preterm birth by cervical ultrasound. *Am J Obstet Gynecol*. 2004;191(4):1393-1397.
73. Goldenberg RL, Culhanes JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. *Lancet*. 2008;371(9606):75-84.
74. Costeloe K, Hennessy E, Gibson AT, Marlow N, Wilkinson AR. The EPICure study; outcomes to discharge from hospital for infants born at the threshold of viability. *Pediatrics*. 2000;106(4): 659-671.
75. Larroque B, Breart G, Kaminski M, et al. Survival of very preterm infants. Epipage, a population based cohort study. *Archdis child fetal neonatal Ed*. 2004;89(2): F139-
-

F144.

76. Draper ES, Manktelow B, Field DJ, James D. Prediction of survival for preterm births by weight and gestational age: retrospective population based study. *BMJ*. 1999;319(7217): 1093-1097.
77. Marlow N, Wolke D, Bracewell MA, Samara M. Neurologic and development disability at six years of age after extremely preterm birth. *N Engl J Med*. 2005;352(1):9-19.
78. Mangham LJ, Petrou S, Doyle LW, Draper ES, Marlow N. The Cost of preterm Birth Throughout Childhood in England and Wales. *Pediatrics*. 2009;123(2):e312-e327.
79. Tracy A. MANUCK, M.D, et al. Preterm Neonatal Morbidity and Mortality by Gestational Age: A Contemporary Cohort. *Am J Obstet Gynecol*. 2016 July ; 215(1): 103.e1–103.e14.
80. American College of Obstetricians and Gynecologists: Management of preterm labor. Practice Bulletin No. 127, June 2012a
81. American College of Obstetricians and Gynecologists: Prediction and prevention of preterm birth. Practice Bulletin No. 130, October 2012b
82. Stoll BJ, Hansen NI, Bell EF, et al: Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. *Pediatrics* 126:443, 2010
83. MC lean M, Walters WA, Smith R. Prediction and early diagnosis of preterm labor: A critical review. *Obstet Gynecol Sur* 1993;48:209-225.

-
84. Lockwood CJ, Senyei AE, Dische MR, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. *N Engl J Med.* 1991;325(10):669-674.
85. Honest H, Bachmann LM, Gupta JK, Kleijnen J, Khan KS. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systemic review. *BMJ.* 2002;325(7359):301.
86. Golden berg RL. The management of Preterm Labour. *Obstet Gynecol* 2002;100:1020-37.
87. Mc Gregor JA, Jackson GM, Lachelin GC, et al. Salivary estriol as risk assessment for preterm labor: a prospective trial. *Am J Obstet Gynecol* 1995;173:1337-42.
88. Francois goffinet. Primary predictors of preterm labor. *Br J Obstet Gynecol*; 2005,vol 112,suppl 1:38-47.
89. Plevyak MP, Lambert –Messerlian GM, Farina A, et al. Concentrations of serum total activating A and inhibin A in preterm and term labour patients; a cross- sectional study. *J Soc Gynecol Investig* 2003;10:231-6.
90. Katz VL, Chercheir NC, Cefalo RC. Unexplained elevation of maternal serum alpha fetoprotein. *Obstet Gynecol Surv.* 1990;45:719-26.
91. Henrik Hagberg, Carina Mallard, Bo Jacobson. Role of Cytokines in preterm Labor and brain injury. *Br J Obstet Gynecol*; 2005,vol 112,supp 1:16-18.
92. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of low birth weight infant. *N Engl J Med.* 1995;333:1737.
-

-
93. Cotch MF, Pastorek JG 2nd, Nugent RP, et al: Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis. 1999;24:353.
94. Martin DH, Eschenbach DA, Cotch MF, et al: Double-blind placebo controlled treatment trial of Chlamydia trachomatis endocervical infections in pregnant women. Infect Dis Obstet Gynecol 1997;10.
95. Wadha PD, Gartie TJ, Porto M, et al. Placental corticotrophin releasing hormone (CRH), spontaneous preterm birth and fetal growth restriction: a prospective investigation. Am J Obstet Gynecol 2004;191:1063-9.
96. John d Yeast, George LU. Biochemical markers for the prediction of preterm labor. Obstet Gynecol Clin N Am 2005;32:369-381.
97. Michael A Elovitz, Joseph Baron and Mark Phillippe. The role of Thrombin in preterm Parturition. Am J Obstet Gynecol Nov 2001;vol 185(5):1059-1063.
98. Roger B Newman. Uterine contraction assessment. Obstet Gynecol Clin N Am 2005 :32;341-367.
99. Robert E Garfield, Willaim L Maner, Holger Maul, George R Saada. Use of Uterine EMG and Cervical LIF in monitoring pregnant patients. Br J Obstet Gynecol; 2005 ,vol 112, Supp 1:103-108.
100. John Studd. Progression in Obstetrics and Gynecology Vol 12. Prediction and Prevention of Preterm birth; 67-80.
101. Owen J, Yost N, Berghella V, et al. Mid-trimester endovaginal sonography in women
-

-
- at high risk for spontaneous preterm birth.JAMA.2001;286(11):1340-1348.
102. Grimes-Dennis J BV. Cervical length and prediction of preterm delivery. Curr opin Obstet Gynecol.2007;19(2):191-195.
- 103.Skentou C, Souka AP, To MS, Liao AW, Nicolaides KH. Prediction of preterm delivery in twins by cervical assessment at 23 weeks. Ultrasound obstet Gynecol.2001;17(1):7-10.
104. Harald Leitich.Secondary Prevention of Preterm Birth.Br J Obstet Gynecol; 2005,vol 112,supp 1:48-50.
- 105.Philip G Stubblefield.Preterm Birth Sec edition,Causes and prevention of premature birth : An overview 1997:24.
106. Andrienne Z Ables,Pharm D,Ana Maria Romero,Suneet P Chauhan. Use of Calcium Channel Antagonists for Preterm labor. Obstet Gynecol Clin N Am 2005;32:519-525.
- 107.Kurzel RB. Serum magnesium levels in pregnancy and preterm labour. Am J Perinatal. 1991 Mar;8(2):119-27.
- 108.Agarwal U,Kapoor M,Singh Sp, et al. A study of serum magnesium level in different types of abortions and preterm labour. J Obst Gynae Ind 1992;42(5):601-6.
- 109.Kamal S. Sharan A, Kumar U. Shashi. Sk. Serum magnesium level in preterm labour. Indian J Pathol Microbiol. 2003 Apr;46(2):271-3.
- 110.Bardicef M,Bardicef O, Sorokin Y, et al. Extracellular and intracellular magnesium
-

-
- depletion in pregnancy and gestational diabetes. Am J Obstet Gynecol 1995;172:1009-1013.
111. Cynthia A Stanldley, Janice E Whitty, Brain A Mason, et al. Serum ionized magnesium levels in normal and preeclamptic gestation. Obstetrics and gynecology, 1997; 89: 24-27.
112. Pennington JA, Young BE. (1991). J Am Diet Assoc: 179-183.
113. Cunze T, et al. Plasma and myometrium electrolyte changes in the last trimester of pregnancy. Geburtshilfe Frauenheilkd 1994; 54(6): 362-366
114. Phillippe M. Cellular mechanisms underlying magnesium sulphate inhibition of phasic myometrial contractions. Biochem Biophys Res Commun, 1998 Nov 18; 252(2): 502-7.
115. Buhimschi I, Yallampalli C, Dong YL, et al. Involvement of a nitric oxide guanosine monophosphate pathway in control of human contractility during pregnancy. Am J Obstet Gynecol. 172: 1577-1584.
116. Knowles RG, Moncada S. Nitric oxide synthase in mammals. Biochem J. 1994; 289: 249-258.
117. Pearson PJ, Evora PRB, Secombe JF, et al. Hypomagnesemia inhibits nitric oxide release from coronary endothelium: protective role of magnesium infusion after cardiac operations. Ann Thorac Surg. 1998; 65: 967-972.
118. Adams Lemancewicz, Halina Laudanska, Tadeusz Laudanski, et al. Permeability of fetal membranes to calcium and magnesium: possible role in preterm labour.
-

Human reproduction.2000;15(9):2018-2022.

119. D. Pushpo and W. M. A. Jagdish, “A study of serum magnesium level in preterm labour,” *Journal of Obstetrics and Gynaecology of India*, vol. 41, pp. 269–273, 1991.
120. Smolarczyk R, Wojcicka-Jagodizinska J, Romejko E, et al. Calcium- phosphate magnesium homeostasis in women with threatened preterm delivery. *Int J Gynecol Obstet* 1997 Apr;57(1):43-47.
121. Crowther A, Brown J, Christopher JD MC Kinlay, Middletn P. Magnesium sulphate for preventing labour. *Conchrane Database of systemic review*. August 2014.
122. Helen C. MC Namara, Crowther A, Brown J. Different treatment regims of magnesium sulphate for tocolysis in women in preterm laboour. *Cochrane databse of systemic review*. December 2015.
123. Shatha A Muhmoud, Ikhlas M. Salch. Huda H Khalaf. The correlation between maternal hypomagnesemia and preterm labour. *Int J Reprod Contaccept Obstet Gynecol*.2106; 5(8). 2571-2575.
124. Ensiyeh J, Pooralajal J. Fereidooni B, Asltoghiri M, Hejrati P. The association between maternal serum magnesium level and pregnancy outcomes. *J Post Med Inst* 2017;31(1): 77-81.
125. Pamela Borja-Del-Rosario, Sudupta. K, Shushama H, Bhutada A, Rostoogi S. Neonatal serum magnesium concentration are determined by total maternal dose of magnesium administered gor neuroprotection. *J Perinat Med*. March 2014.42 (2).

-
126. Michael J. Stark, Nicolette A. Hodyl and Chad C. Andersen. Effects of antenatal magnesium sulfate treatment for neonatal neuro-protection on cerebral oxygen kinetics. Int J Pediatric Research Foundation. July 2015.
127. Betsy O, Tyler B, Ernest K, Tom G, Joshua B. Neonatal Magnesium level between 24 and 48 hours of life and outcomes for epilepsy and motor impairment in premature infants. J. Pediatr Neurol. November 2016.
128. Sajad R, Fuat Emre C, Mehmet Yekta O, Evli A, Ugar G, Hussain P et al., Multicenter Randomized Controlled Trial of Therapeutic Hypothermia Plus Magnesium Sulfate Versus Therapeutic Hypothermia Plus Placebo in the Management of Term and Near-term Infants with Hypoxic Ischemic Encephalopathy (The Mag Cool Study): A Pilot Study. J of Clinical Neonatology. September 2015. 4(3). 158-163.
129. Jenabi E, , Poorolajal J, Fereidooni B, Asltoghiri M, Hejrati P. The association between maternal serum magnesium level and pregnancy outcomes. J Postgrad Med Inst 2017; 31(1): 77-81.
130. Durlach J, Bac P, Durlach V, Bara M, Guet-Bara A. Neurotic, neuromuscular and autonomic nervous form of magnesium imbalance. Magnesium Res 1997; 10: 169-95.
131. Sharma A, Kharb S, Vineeta, Gulati N. Serum magnesium levels in preterm labour in relation to socioeconomic status. Indian Journal of Biochemistry. 1998;13:123-5.
132. Khani S, Shokrzadeh M, Karamoddini PK, Shahmohammadi S. The relationship between maternal serum magnesium level and preterm birth. Pakistan Journal of

Biological Sciences.2010;13:335-9.

133. Shatha A. Mahmoud, Ikhlas M. Saleh, Huda H. Khalaf. The correlation between maternal hypomagnesemia and preterm labour. *Int J Reprod Contracept Obstet Gynecol.* 2016 Aug;5(8):2571-2575.
134. Watson PE, McDonald BW. The association of maternal diet and dietary supplement intake in pregnant New Zealand women with infant birthweight. *Eur J Clin Nutr* 2010;64:184-93.
135. Elezabeth KE, Krishnan V, Vijayakumar T. Umbilical cord blood nutrients in low birth weight babies in relation to birth weight and gestational age. *Indian J Med Res.*2008; 128:128-133.
136. Pourarian S, Namavar Jahromi B, F T. The Relationship between Maternal Serum Magnesium Level and Infant LowBirth Weight in Hafez Hospital, Shiraz, Iran. *Iran J Neonat*2014; 5:1-6.
137. Spatting L. Magnesium in obstetrics and gynaecology. *Gynakol Geburtshilfliche Rundsch.*2004;33:85-91.

PERFORMA: (STUDY GROUP)

- 1 .Name of the patient:
2. Age:
3. Hospital no:
4. Marital status:
5. Husband name:
6. Occupation:
7. Husband's occupation:
8. Socioeconomic status:
9. H/o amenorrhoea:
10. Chief complaints

11. H/o presenting illness:
12. H/o present pregnancy:
1st trimester:

2nd trimester:

3rd trimester:

13. H/o presence of muscle cramps during pregnancy
14. Any changes in the quality and quantity of vaginal discharge.
15. H/o pre eclampsia and imminent signs
16. H/o bleeding pv

-
17. H/o pv leak
 18. H/o fever
 19. H/o burning micturition
 20. H/o previous surgery
 21. H/o medical illness like HTN, DM, BA, thyroid or cardiac anomalies.
 22. H/o abortions
 23. H/o preterm delivery
 25. H/o multiple pregnancy
 26. Patients with uterine malformations

27. married life - marriage-

28. Gravida -

Para- Living- Abortion- Dead-

Last child birth

29. Outcome of pregnancy:

30. H/o contraception:

31. Menstrual history:

- PMC
- a. age of menarche
 - b. duration
 - c. cycle
 - d. no. of pads used per day
 - e. associated with dysmenorrhoea or clots

LMP-

EDD-

POG-

32. GENERAL PHYSICAL EXAMINATION:

Built a. poor

b. moderate

c. obese

Febrile/ afebrile

Pallor Icterus Clubbing Cyanosis Koilonychia
Lymphadenopathy Edema

BP-

PR-

CVS:

RES:

CNS:

P/A: uterus size

Acting / relaxed

Lie

Presentation

FHR

P/S:

P/V:

33. INVESTIGATION:

a. CBC

hb

Plt

Tlc-

Dlc-

b. urine routine:

c Hbsag

HIV

VDRL

d. OGCT with 75mg glucose :

e. Serum magnesium (study group) :

f. USG:

34. CONTROL GROUP :

Outcome of labour:

- a. Date of delivery:
- b. Time of delivery:
- c. Type of delivery :
 - 1. Spontaneous vaginal delivery
 - 2. Forceps
 - 3. Ventouse
 - 4. LSCS (along with indication)

BABY NOTES :

- a. Male / female
- b. Live / still birth
- c. Birth weight
- d. Apgar score
 - 1' - 5' –
- e. NICU admission:
- f. Follow up in NICU:

Take home baby :

PERFORMA: (CONTROL GROUP)

1. Name of the patient:
2. Age:
3. Hospital no:
4. Marital status:
5. Husband name:
6. Occupation:
7. Husband's occupation:
8. Socioeconomic status:
9. H/o amenorrhoea:
10. Chief complaints

11. H/o presenting illness:
12. H/o present pregnancy:
1st trimester:

2nd trimester:

3rd trimester:

13. H/o presence of muscle cramps during pregnancy
14. Any changes in the quality and quantity of vaginal discharge.
15. H/o pre eclampsia and imminent signs
16. H/o bleeding pv

-
17. H/o pv leak
 18. H/o fever
 19. H/o burning micturition
 20. H/o previous surgery
 21. H/o medical illness like HTN, DM, BA, thyroid or cardiac anomalies.
 22. H/o abortions
 23. H/o preterm delivery
 25. H/o multiple pregnancy
 26. Patients with uterine malformations

 27. married life - marriage-
 28. Gravida -
 - Para- Living- Abortion- Dead-
 - Last child birth
 29. Outcome of pregnancy:
 30. H/o contraception:
 31. Menstrual history:
 - PMC a. age of menarche
 - b. duration
 - c. cycle
 - d. no. of pads used per day
 - e. associated with dysmenorrhoea or clots
 - LMP-
 - EDD-
-

POG-

32. GENERAL PHYSICAL EXAMINATION:

Built a. poor

b. moderate

c. obese

Febrile/ afebrile

Pallor Icterus Clubbing Cyanosis Koilonychia
Lymphadenopathy Edema

BP-

PR-

CVS:

RES:

CNS:

P/A: uterus size

Acting / relaxed

Lie

Presentation

FHR

P/S:

P/V:

33. INVESTIGATION:

a. CBC

hb

Plt

Tlc-

Dlc-

b. urine routine:

c Hbsag

HIV

VDRL

d. OGCT with 75mg glucose :

e. Serum magnesium (control group) :

f. USG:

34. CONTROL GROUP :

Outcome of labour:

- d. Date of delivery:
- e. Time of delivery:
- f. Type of delivery :
 - 5. Spontaneous vaginal delivery
 - 6. Forceps
 - 7. Ventouse
 - 8. LSCS (along with indication)

BABY NOTES :

- g. Male / female
- h. Live / still birth
- i. Birth weight
- j. Apgar score
 - 1' - 5' –
- k. NICU admission:
 - l. Follow up in NICU:
- m. Take home baby :

**SRI DEVARAJ URS MEDICAL COLLEGE & RESEARCH CENTRE,
TAMAKA, KOLAR**

PATIENT CONSENT FORM

Case no:

I have read the foregoing information, or it has been read to me. I have had the opportunity to ask questions about it and any questions that I have asked have been answered to my satisfaction. I have understood that I have the right to refuse consent or withdraw it at any time during the study and this will not affect my treatment in any way. I consent voluntarily to participate in this study “ **EVALUATION OF SERUM MAGNESIUM LEVEL IN PRETERM LABOUR**”

Name of Participant_____

Signature/ thumb print of Participant _____

Date _____

Statement by the researcher/person taking consent:

I have accurately read out the information sheet to the potential participant, and to the best of my ability made sure that the participant understands that the following will be done:

1. Blood sample will be taken from the patient for serum MAGNISIUM analysis.

I confirm that the participant was given an opportunity to ask questions about the study, and all the questions asked by the participant have been answered correctly and to the best of my ability. I confirm that the individual has not been coerced into giving consent, and the consent has been given freely and voluntarily.

Name of Researcher/person taking the consent_____

Signature of Researcher /person taking the consent_____

Date _____

Name and Address of Principal Investigator: Dr.Phurailatpam. Priyadarshini.

R.L Jalappa Hospital

Tamaka, Kolar.

ಒಪ್ಪಿಗೆ ಪತ್ರ / ರೂಪ

ಮಾನ್ಯರೆ,

ನಾವು ನಡೆಸಿತ್ತಿರುವ ಸಂಶೋಧನಾ ವಿಷಯ ವಾದ " EVALUATION OF SERUM MAGNISIUUM LEVEL IN
PRETERM LABOUR " ದಲ್ಲಿ ಭಾಗವಹಿಸಲು ಅನುಮತಿಯನ್ನು ಕೋರುತ್ತಿದ್ದೇವೆ.

ನಿಮ್ಮ ಭಾಗವಹಿಸುವಿಕೆಯ ಸಂಪೂರ್ಣವಾಗಿ ನಿಮ್ಮ ಇಚ್ಛಾನುಸಾರವಾಗಿದ್ದು ಇದರಲ್ಲಿ ಬಗೆಗೆ ನಿಮ್ಮ ನಿರ್ಧಾರವು ನಿಮ್ಮ
ಮತ್ತು ಆಸ್ಪತ್ರೆಯ ನಡುವಿರುವ ಸಂಬಂಧದ ಮೇಲೆ ಯಾವುದೇ ರೀತಿಯ ಪರಿಣಾಮವನ್ನು ಬೀರುವುದಿಲ್ಲ ಮತ್ತು
ಭಾಗವಹಿಸಲು ನಿಮ್ಮ ಒಪ್ಪಿಗೆಯಿದ್ದರೆ ಈ ಸಂಶೋಧನಾ ಕಾರ್ಯಕ್ರಮದಿಂದ ಯಾವುದೇ ಕ್ಷಣದಲ್ಲಿ ಹಿಂಜರಿಯ ಬಹುದಾದ
ಅವಕಾಶ ಇರುತ್ತದೆ.

ಈ ಸಂಶೋಧನೆಯಿಂದಾಗಿ ನಿಮ್ಮ ದೇಹದ ಮೇಲೆ ಯಾವುದೇ ದುಷ್ಪರಿಣಾಮವಾಗುವುದಿಲ್ಲ.

ನಿಮ್ಮ ಭಾಗವಹಿಸುವಿಕೆಯ ಬಗೆಗೆ ಗೌಪಾತ್ಯಯನ್ನು ಕಾಪಾಡಲಾಗುತ್ತದೆ ಹಾಗೂ ಮಾಹಿತಿಯ ಬಾರಿ ನಮ್ಮ ಸಂಶೋಧನಾ
ತಂಡದವರಿಗೆ ಮಾತ್ರ ತಿಳಿದಿರುತ್ತದೆ.

ಇದರ ಬಗೆಗಿರುವ ಎಲ್ಲಾ ಅನುಮಾನಗಳನ್ನು ಹಾಗೂ ಪ್ರಶ್ನೆಗಳನ್ನು ಯಾವುದೇ ನಿರ್ಭಂದವಿಲ್ಲದೆ, ಯಾವುದೇ
ಸಮಯದಲ್ಲಿ ನೀವು ನಿಮ್ಮ ತಂಡದೊಂದಿಗೆ ಚರ್ಚಿಸಬಹುದು.

ಇದರಲ್ಲಿ ಭಾಗವಹಿಸಲು ತಾವು ಮನಸ್ಸೊಪ್ಪಕವಾಗಿ ಇಚ್ಛೆವಿದ್ದರೆ ದಯವಿಟ್ಟು ಇಲ್ಲಿ ಸಹಿ ಮಾಡಿ.

ಭಾಗವಹಿಸುವ ಮಹಿಳೆಯರ ಸಹಿ

ದಿನಾಂಕ :

ಸಾಕ್ಷಿಗಾರರ ಸಹಿ:

PATIENT INFORMATION SHEET

Study title: EVALUATION OF SERUM MAGNESIUM LEVEL IN PRETERM LABOUR.

Study location: R L Jallappa Hospital and Research Centre attached to Sri Devraj Urs Medical College. Tamaka, Kolar

Details-

The study will be taken up in the patients presenting between 28 to 37 weeks of gestation. The blood sample will be evaluated for serum magnesium level.

Patients in this study will have to undergo routine blood investigations such as complete blood count, viral serology, urine routine and random blood sugar levels. To assess the fetal wellbeing and an obstetric ultrasound with biophysical profile will also be done.

Please read the following information and discuss with your family members. You can ask any question regarding the study. If you agree to participate in the study we will collect information (as per proforma) from you or a person responsible for you or both. Relevant history will be taken. This information collected will be used only for dissertation and publication.

All information collected from you will be kept confidential and will not be disclosed to any outsider. Your identity will not be revealed. This study has been reviewed by the Institutional Ethics Committee and you are free to

contact the member of the Institutional Ethics Committee. There is no compulsion to agree to this study. The care you will get will not change if you don't wish to participate. You are required to sign/ provide thumb impression only if you voluntarily agree to participate in this study.

For further information contact

Dr.Phurailatpam. Priyadarshini.

Post graduate . phone no. 9612169373

Department of obstetrics and gynecology, SDUMC , Kolar.

PATIENT INFORMATION SHEET (KANNADA)

ಅಧ್ಯಾನಹೆಸರು

- EVALUATION OF SERUM MAGNESIUM LEVEL IN PRETERM LABOUR.

ಕೆಳಗಿನಮಾಹಿತಿಯನ್ನು ಓದಲು ಮತ್ತು ನಿಮ್ಮ ಕುಟುಂಬದ ಸದಸ್ಯರು ಚರ್ಚಿಸಬೇಕಾದ ಯಾವಿಷ್ಟು ನೀವು ಅಧ್ಯಯನ ಬಗ್ಗೆ ಯಾವುದೇ ಪ್ರಶ್ನೆ ಕೇಳಬಹುದು. ನೀವು ಅಧ್ಯಯನದಲ್ಲಿ ಭಾಗವಹಿಸಲು ಒಪ್ಪಿದಲ್ಲಿ ನಾವು ನೀವು ಅಥವಾ ನೀವು ಅಥವಾ ಎರಡೂ ನಿರ್ವಹಿಸುವ ವ್ಯಕ್ತಿರಿಂದ (Proforma ಪ್ರಕಾರ)

ಮಾಹಿತಿಯನ್ನು ಸಂಗ್ರಹಿಸುತ್ತದೆ. ಸಂಬಂಧಿತ ಇತಿಹಾಸ ತಿಳಿದುಕೊಳ್ಳಲಾಗುವುದು. ಸಂಗ್ರಹಿಸಿದ ಈ ಮಾಹಿತಿಯನ್ನು ಪ್ರೌಢಪ್ರಬಂಧದಲ್ಲಿ ಮತ್ತು ಪ್ರಕಟಣೆಗಳಲ್ಲಿ ಬಳಸಲಾಗುತ್ತದೆ.

ನೀವು ಸಂಗ್ರಹಿಸಿದ ಎಲ್ಲಾ ಮಾಹಿತಿಯನ್ನು ಗೌಪ್ಯವಾಗಿ ಇಡಲಾಗುತ್ತದೆ ಮತ್ತು ಯಾವುದೇ ಹೊರಗಿನ ವರದಿ ರಂಗ ಮಾಡಲಾಗುವುದಿಲ್ಲ. ನಿಮ್ಮ ಗುರುತನ್ನು ತೋರಿಸಲಾಗುವುದಿಲ್ಲ.

ಈ ಅಧ್ಯಯನವು ನೈತಿಕ ಸಮಿತಿಯ ವಿಮರ್ಶೆ ಮತ್ತು ನೀವು ನೈತಿಕ ಸಮಿತಿಯ ಸದಸ್ಯ ಸಂಪರ್ಕಿಸಲು ಉಚಿತ.

ಈ ಅಧ್ಯಯನದಲ್ಲಿ ಒಪ್ಪಿಕೊಳ್ಳಲು ಯಾವುದೇ ಕಡ್ಡಾಯ ಇಲ್ಲ.

ನೀವು ಭಾಗವಹಿಸಲು ಇಚ್ಛಿಸಿದಿದ್ದರೆ ನೀವು ಪಡೆಯುತ್ತಾನೆ ರಕ್ಷಣೆ ಬದಲಾಗುವುದಿಲ್ಲ. ನೀವು /

ಸೈನ್ಸೀವು ಸ್ವಯಂಪ್ರೇರಣೆಯಿಂದ ಈ ಅಧ್ಯಯನದಲ್ಲಿ ಭಾಗವಹಿಸಲು ಒಪ್ಪುತ್ತೀರಿ ಮಾತ್ರ ಹೆಚ್ಚು ಟ್ರಿನಗುರು ತುಂಬದಿಗಿರುವ ಅಗತ್ಯವಿದೆ.

ಹೆಚ್ಚಿನ ಮಾಹಿತಿಗಾಗಿ ಸಂಪರ್ಕಕ್ಕೆ

Dr. priyadarshini.

ಸ್ನಾತಕೋತ್ತರ

ಪ್ರಸೂತಿ ಮತ್ತು ಸ್ತ್ರೀರೋಗ ಶಾಸ್ತ್ರಜ್ಞರಾದ

* SDUMC, ಕೋಲಾರ

NAME	IP.NO.	AGE	DOA	BOOKED	PARITY	GA	SE STATUS	ANC	RELIGION	S.MG mg/dl	DOD	MOD	SEX	WEIGHT	APGAR 1min	APGAR 5min	NICU
Roopa	286627	26	5/11/2016	unbooked	primi	36+1	low middle	nil	hindu	1.1	5/11/2016	ptvd	male	2.1 kg	6-Jan	8-Jan	yes
chaitra	284323	20	5/5/2016	unbooked	primi	35+1	low middle	nil	hindu	1.2	5/5/2016	ptvd	female	1.9 kg	6-Jan	8	yes
gyathri	229270	26	12/6/2015	booked	primi	35+6	middle	nil	hindu	1.2	12/7/2015	lscs	femlae	2 kg	7	9	yes
shabana	256914	19	12/15/2016	booked	primi	36+4	low middle	nil	islam	1.1	12/15/2016	lscs	male	2.4kg	7	9	mother side
tabassum	229277	25	12/6/2015	unbooked	G2P1	34+6	low middle	nil	islam	1.3	12/6/2015	ptvd	male	i.8kg	6	8	yes
mounika	299697	21	2/6/2016	unbooked	G2P1	35+4	low middle	rh negative	hindu	1.4	2/6/2016	ptvd	female	2kg	7	9	yes
kalavathi	281327	30	5/7/2016	unbooked	G3P2L2	33+2	low middle	nil	hindu	1.6	5/7/2016	ptvd	male	1.7kg	6	8	yes
satya	300021	20	3/10/2016	unbooked	primi	32+3	low	nil	hindu	1.1	3/10/2016	ptvd	male	1.5kg	5	7	yes
preeti	256899	19	2/17/2016	unbooked	primi	33+4	low	nil	hindu	1.2	2/17/2016	ptvd	female	1.76kg	6	8	yes
baby rani	293711	22	3/4/2016	unbooked	G2P1	34+2	low middle	nil	hindu	1.3	3/4/2016	ptvd	male	2kg	6	8	yes
shantama	194322	19	9/11/2015	booked	primi	36	middle	cont pelvis	hindu	1.1	9/12/2015	lscs	male	2.4kg	7	9	mother side
rathnama	197130	22	9/20/2015	unbooked	G2P1	36	middle	nil	hindu	1.3	9/20/2015	ptvd	female	2.3kg	7	9	mother side
anitha	202342	29	10/5/2015	unbooked	G3P2L2	34+1	low	nil	hindu	1.4	10/6/2015	ptvd	male	1.67kg	6	8	yes
pravabathi	206715	20	10/11/2015	unbooked	primi	33+4	low	breech	hindu	1.3	10/11/2015	asst breech	male	1.8kg	6	8	yes
renuka	203038	24	10/14/2015	booked	primi	36+4	low middle	rh negative	hindu	1.1	10/15/2015	ptvd	female	2.5kg	7	8	mother side
radha	214642	25	10/29/2015	unbooked	G3P2L2	35+5	middle	nil	hindu	1.3	10/29/2015	out forcep	male	2.3kg	7	9	mother side
gulzar begum 119591		23	10/31/2015	booked	primi	36+4	upper mid	transvere lie	islam	1.5	10/31/2015	lscs	male	2.5kg	7	9	mother side
sujatha	208502	26	11/10/2015	unbooked	G4P3L2D1	33+2	upper mid	nil	hindu	1.6	11/11/2015	ptvd	female	1.3kg	6	8	yes
archana	226579	19	12/8/2015	booked	primi	35+6	middle	rh negative	hindu	1.5	12/9/2015	lscs	male	2.2kg	7	9	yes
ambika	231037	20	12/9/2015	unbooked	G2P1	34+5	low middle	nil	hindu	1.4	12/10/2015	ptvd	female	2.2kg	6	8	yes
tasmeen	224129	21	11/23/2015	booked	primi	36+4	low middle	rh negative	islam	1.3	11/24/2015	out forcep	male	2.4kg	7	9	mother side
radha bai	229338	27	12/22/2015	unbooked	G4P3L2D1	34+1	low middle	nil	hindu	1.4	12/23/2015	ptvd	female	1.87kg	6	8	yes
asha	237650	22	12/28/2015	unbooked	primi	36+3	middle	transvere lie	islam	1.3	12/29/2015	lscs	male	2.47kg	7	9	mother side
jayama	257226	26	2/19/2016	unbooked	g3P2L2	36+4	middle	nil	hindu	1.5	2/20/2016	ptvd	female	2.5kg	7	9	mother side
rathnama	256911	24	2/29/2016	booked	primi	36+2	upper mid	rh negative	hindu	1.5	6/29/2016	lscs	male	2.48kg	7	9	mother side
bhavya	265900	22	3/25/2016	unbooked	G2P1	33+5	low	nil	hindu	1.4	3/25/2016	ptvd	male	1.79kg	6	8	yes
shobha	280100	23	4/24/2016	booked	primi	36+4	upper mid	breech	hindu	1.5	4/25/2026	lscs	male	2.6kg	7	9	mother side
shashikala	281892	24	5/11/2016	unbooked	G2P1	35+4	middle	nil	hindu	1.4	5/12/2016	ptvd	female	2 kg	7	9	yes
lakshmama	285752	22	5/23/2016	booked	G3P2L2	34+2	middle	nil	hindu	1.3	5/23/2026	ptvd	male	1.9 kg	7	9	yes
gyathri	295280	22	5/30/2016	booked	primi	36+4	low middle	nil	hindu	1.3	5/31/2016	lscs	female	2.3kg	7	9	mother side
shabren taj	250583	19	2/10/2016	unbooked	primi	35+5	low	nil	islam	1.2	2/10/2016	ptvd	male	1.88kg	6	8	yes
ashma	266876	18	3/19/2016	unbooked	primi	35+3	upper mid	nil	islam	1.4	3/20/2016	ptvd	female	2.1kg	7	9	yes
pravavathi	300958	20	6/21/2016	unbooked	G2P1	32+6	upper mid	nil	hindu	1.5	6/22/2016	ptvd	male	1.76kg	6	8	yes
ayesha	281851	18	4/26/2016	unbooked	primi	33+5	low	rh negative	islam	1.4	4/27/2016	out forcep	male	1.8kg	6	8	yes
subha	305359	25	6/29/2016	booked	G2P1	36+5	middle	breech	hindu	1.4	6/29/2016	lscs	female	2.5kg	7	9	mother side
shanta	307018	28	7/7/2016	booked	G3P2L2	36+4	middle	nil	hindu	1.6	7/8/2016	ptvd	male	2.6kg	7	9	mother side
pravathi	308378	24	7/16/2016	unbooked	primi	35+6	upper mid	nil	hindu	1.7	7/16/2016	lscs	female	2.63kg	7	9	mother side
nazma	295345	20	6/2/2016	unbooked	G3P2L2	34+4	low middle	rh negative	islam	1.3	6/2/2016	ptvd	male	1.79kg	6	8	yes
ayesha	405580	19	3/3/2017	unbooked	primi	35+2	upper mid	breech	islam	1.4	3/3/2017	lscs	female	2.1kg	7	9	yes
sulochana	359484	22	11/14/2016	booked	primi	36+4	upper mid	nil	hindu	1.6	11/15/2016	ptvd	male	2.5kg	7	9	mother side
shanaz	322920	21	8/18/2016	unbooked	primi	33+1	low	nil	islam	1.2	8/19/2016	ptvd	female	1.62kg	6	8	yes
baby	451913	26	7/10/2017	booked	G2P1	36+4	upper mid	nil	hindu	1.9	7/11/2017	ptvd	male	2.6kg	7	9	mother side
arfa katum	317756	22	8/4/2016	booked	primi	36+5	upper mid	cont pelvis	islam	1.8	8/5/2016	lscs	female	2.5kg	7	9	mother side
niha begum	343158	18	9/22/2016	unbooked	primi	33+5	low	nil	islam	1.3	9/23/2016	ptvd	male	1.86kg	6	8	yes
savitha	455516	26	7/17/2017	unbooked	G2P1	34+5	upper mid	nil	hindu	1.3	7/17/2017	ptvd	female	1.98kg	7	9	yes
prabhavati	456773	23	7/26/2017	booked	primi	36+5	upper mid	nil	hindu	2	7/26/2017	lscs	female	2.4kg	7	9	mother side
manjula	448823	18	6/29/2017	unbooked	primi	34+2	middle	nil	hindu	1.4	6/29/2017	ptvd	male	1.69kg	7	9	yes
hulsna	373123	19	8/12/2016	unbooked	primi	35+4	low middle	nil	islam	1.3	8/12/2016	out forcep	male	2.1kg	6	8	yes
salma	378047	24	12/22/2016	unbooked	G2P1	34+2	low	nil	islam	1.3	12/23/2016	ptvd	female	2kg	7	9	yes
manasa	455516	22	7/10/2017	unbooked	primi	36+4	middle	nil	hindu	1.5	7/10/2017	ptvd	male	2.1kg	7	9	yes

NAME	IP.NO	AGE	BOOKED	PARITY	GA TEST	GA delivery	ANC complications	RELIGION	SE STATUS	MG mg/dl	MOD	SEX	WEIGHT	AGPAR 1min	APGAR 5 min	OUTCOME
chaitra	456127	24	booked	primi	32+3	38+6	nil	hindu	middle	2.3	ftvd	male	2.7kg	7	9	mother's side
nithiya	452357	22	booked	G2P1L1	34+2	40+2	nil	hindu	upper mid	1.9	ftvd	female	2.8kg	7	9	mother's side
rajamma	194920	26	booked	G3P2L2	29+6	38+1	previous lscs	hindu	upper mid	2.4	lscs	male	2.87kg	7	9	mother's side
swathi	196191	19	booked	primi	30	37+6	nil	hindu	upper mid	2.1	out force	male	3.01kg	7	9	mother's side
farzana	203407	20	booked	G2P1L1	32+2	38+2	previous lscs	islam	upper mid	2.1	lscs	male	3.15kg	7	9	mother's side
padmavathi	202121	22	booked	primi	32+6	40+2	nil	hindu	middle	2.2	ftvd	female	2.7kg	7	9	mother's side
kousalya	203407	21	booked	G2P1L1	34+2	38+4	rh negative	hindu	upper mid	1.9	ftvd	female	2.89kg	7	9	mother's side
su hail taj	224650	23	booked	primi	30+1	39+5	nil	islam	middle	2.3	ftvd	male	2.97kg	7	9	mother's side
zaith unisa	209663	19	booked	primi	34+3	38+5	nil	islam	upper mid	2.1	ftvd	female	2.98kg	7	9	mother's side
kousalya	203407	24	booked	G3P2L2	34+1	39+4	nil	hindu	upper mid	1.9	ftvd	male	3.34kg	7	9	mother's side
bhavya	205623	28	booked	G2P1L1	33+2	38+6	nil	hindu	middle	2.4	ftvd	female	2.97kg	7	9	mother's side
aruna	212011	25	booked	G3p2L1D1	30+2	39+1	nil	hindu	upper mid	2.5	ftvd	male	2.79kg	7	9	mother's side
dilshad	274744	29	booked	G2A1	30+4	37+4	nil	islam	middle	2.1	ftvd	male	3.06kg	7	9	mother's side
shanta	218852	30	booked	G4P2L2A1	32+3	38+6	nil	hindu	middle	1.9	ftvd	female	3.05kg	7	9	mother's side
pavithra	211174	22	booked	primi	34+1	39+5	nil	hindu	upper mid	1.9	out force	male	3.4Kg	7	9	mother's side
lalitha	223759	24	booked	G2A1	35+2	40+1	nil	hindu	middle	1.9	ftvd	female	3.45Kg	7	9	mother's side
usha	224571	19	booked	primi	29+3	37+6	nil	islam	middle	2.1	lscs	male	2.8kg	7	9	mother's side
suhasani	221264	26	booked	G3P1L1A1	30+2	38+1	previous lscs	hindu	upper mid	2.1	lscs	female	2.97kg	7	9	mother's side
somya	195172	22	booked	primi	34+4	38+2	nil	islam	upper mid	1.9	ftvd	male	3.2kg	7	9	mother's side
ashwini	226544	25	booked	G2P1L1	31+2	38+1	previous lscs	hindu	upper mid	2.4	lscs	female	3.46kg	7	9	mother's side
pramella	235527	19	booked	primi	32+2	39+3	nil	hindu	middle	2.1	ftvd	male	3.2kg	7	9	mother's side
manjula	257226	24	booked	G2A1	35+2	40+1	nil	hindu	middle	1.8	ftvd	female	3.1kg	7	9	mother's side
suma	258143	21	booked	primi	32+1	38+4	rh negative	hindu	middle	2.1	ftvd	male	3.2kg	7	9	mother's side
usha	256911	19	booked	primi	33+4	39+1	nil	hindu	low mid	1.9	lscs	female	2.8kg	7	9	mother's side
shashikala	260624	22	booked	primi	32+4	40+1	nil	hindu	middle	2.3	out force	male	3.5kg	7	9	mother's side
roopa	266097	20	booked	G2A1	35+2	37+5	nil	islam	low mid	1.8	ftvd	female	2.6kg	7	9	mother's side
muniyama	236773	26	booked	G3P2L2	32+1	38+3	nil	hindu	middle	2.2	ftvd	male	2.8Kg	7	9	mother's side
shoba	282430	23	booked	primi	33+6	38+4	nil	hindu	upper mid	2.3	vacum	male	3.46kg	7	9	mother's side
heena kouser	229756	18	booked	primi	34+5	37+6	rh negative	islam	middle	1.8	ftvd	male	2.7kg	7	9	mother's side

shilpa	257436	23	booked	G2P1L1	29+4	38+5		nil		hindu	middle	2.4	ftvd	female	2.98kg	7		9		mother's side	
farah	231213	27	booked	G3P1L1A1	33+3	38+2		previous lscs		islam	upper mid	1.9	lscs	female	3.3kg	7		9		mother's side	
fathima	233173	19	booked	primi	34+2	37+4		nil		islam	middle	1.8	ftvd	male	2.68kg	7		9		mother's side	
shavama	217736	20	booked	primi	30+2	38+5		nil		hindu	upper mid	2.3	ftvd	female	3.5Kg	7		9		mother's side	
safiya	287402	19	booked	primi	29+5	38+6		nil		hindu	middle	2.3	lscs	male	3.03kg	7		9		mother's side	
amravathi	286537	24	booked	G2A1	30+4	40+3		nil		hindu	upper mid	1.8	ftvd	female	3.4kg	7		9		mother's side	
tasmiya	287437	19	booked	primi	34+3	39+3		nil		islam	middle	1.7	out force	male	2.98kg	7		9		mother's side	
asha	294144	22	booked	G2P1L1	32+4	39+6		rh negative		hindu	middle	1.9	ftvd	female	3.07kg	7		9		mother's side	
sumitra	290011	23	booked	primi	29+2	38+4		nil		hindu	upper mid	2.3	ftvd	male	3.5kg	7		9		mother's side	
radha	300487	26	booked	G3P2L2	30+3	39+6		nil		hindu	middle	2.2	ftvd	female	3.47kg	7		9		mother's side	
somya	300837	20	booked	primi	33+1	40+2		nil		hindu	upper mid	1.9	lscs	male	3.6g	7		9		mother's side	
swetha	302727	26	booked	G3P1L1A1	32+4	38+2		nil		hindu	middle	2.1	ftvd	female	2.98kg	7		9		mother's side	
pavithra	304164	19	booked	primi	30+2	38+5		nil		hindu	middle	2.2	ftvd	male	3.04kg	7		9		mother's side	
asma	308402	19	booked	primi	32+1	39+1		nil		islam	low mid	2	ftvd	female	2.6kg	7		9		mother's side	
gyatri	301239	21	booked	G2P1L1	34+2	38+2		previous lscs		hindu	middle	1.9	lscs	male	3.4kg	7		9		mother's side	
ramya	303576	25	booked	primi	32+2	38+6		nil		hindu	middle	2	lscs	male	2.87kg	7		9		mother's side	
fouziya	386589	19	booked	G2A1	35+4	37+5		nil		islam	upper mid	1.9	ftvd	female	2.58kg	7		9		mother's side	
nandini	339482	26	booked	G2P1L1	32+4	38+1		previous lscs		hindu	upper mid	2	lscs	male	3.5kg	7		9		mother's side	
anitha	384687	20	booked	primi	30+6	39+4		nil		hindu	middle	2.2	ftvd	female	3.3kg	7		9		mother's side	
lakshimi	355455	22	booked	primi	29+3	38+4		nil		hindu	upper mid	2.3	ftvd	male	3.45kg	7		9		mother's side	
sabeena	455675	19	booked	primi	30+2	38+4		nil		islam	middle	2.1	ftvd	female	3.2kg	7		9		mother's side	